

## **LICENSE AGREEMENT**

This License Agreement (this “**Agreement**”) is made as of November 15, 2021 (the “**Effective Date**”) by and between:

**PF PRISM HOLDINGS B.V.**, a private limited company (besloten vennootschap) registered under the laws of the Netherlands and having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“**Pfizer**”);

## **AND**

**MEDICINES PATENT POOL FOUNDATION**, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at 7 rue de Varembe Geneva 1202, Switzerland (“**MPP**”).

Each of Pfizer and MPP is referred to in this Agreement individually as a “**Party**” and collectively as the “**Parties**”.

## **RECITALS**

WHEREAS, MPP is a non-profit organization with a mission to improve the health of people living in the developing world by increasing access to quality, safe, efficacious, and affordable medicines by facilitating access to intellectual property on these medicines;

WHEREAS, Pfizer or its Affiliates holds rights to certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined), regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product;

WHEREAS, Pfizer has the right to grant licenses under the Patents and Licensed Know-How and wishes to voluntarily grant such licenses as set forth herein in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);

WHEREAS, MPP is desirous of obtaining, and Pfizer is willing to grant, a license under the Patents under the terms and conditions set forth herein;

WHEREAS, the Parties agree that this Agreement is entered due to the unique situation of the global COVID-19 situation and solely for the purpose of improving access to COVID-19 medicines in the Territory and shall in no way set a precedent for any future potential engagements; and

WHEREAS, the intent of this Agreement is to provide a license to Patents and Licensed Know-How as set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

**1. DEFINITIONS**

- 1.1 “**Affiliate**” shall mean in relation to a Party, any corporation, firm, partnership or other entity that controls, is controlled by or is under common control with that Party, but only for so long as such control continues. For the purposes of this definition, “control” (including with the correlative meanings “controlled by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interests (whether directly or pursuant to any option, warrant, or other similar agreement) of such entity.
- 1.2 “**Agency**” shall mean, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of a regulatory approval or, to the extent required in such country, price approval, for a pharmaceutical product in such country.
- 1.3 “**Agreement Quarter**” shall mean any period of three (3) months ending on the last day of February or May or August or November.
- 1.4 “**Applicable Law**” shall mean any and all laws, statutes, ordinances, regulations, permits, orders, decrees, judgments, directives, rulings or rules of any kind whatsoever that are promulgated by a federal, state, provincial, municipal, or other Governmental Authority or Agency, in each case pertaining to any of the activities contemplated by this Agreement, including any regulations promulgated thereunder, all as amended from time to time.
- 1.5 “**Business Day**” shall mean a day (other than a Saturday or Sunday) on which the banks are open for normal business in New York, USA.
- 1.6 “**Calendar Quarter**” shall mean any period of three (3) months ending on the last day of March or June or September or December.
- 1.7 “**Commercialize**” or “**Commercialization**” shall mean sale, import, or export of the Licensed Product by the Sublicensee to an unrelated entity solely for the purposes of making the Licensed Product available in the Territory for use in the Field.
- 1.8 “**Compound**” shall mean (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-Cyano-2-[(3*S*)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-*N*-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, which has the molecular formula C<sub>23</sub>H<sub>32</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> and having the structure to be set forth on **Exhibit A** attached hereto, as referred to internally by Pfizer as PF-07321332. For clarity, “Compound” includes all forms of (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-Cyano-2-[(3*S*)-2-

oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, including but not limited to, isomers, stereoisomers, diastereomers, tautomers, hydrates, solvates, crystal forms including crystalline forms and co-crystalline forms, amorphous forms, polymorphs, metabolites and prodrugs thereof. Additionally, “Compound” includes all deuterated forms.

- 1.9 “**Control**” or “**Controlled**” shall mean, with respect to intellectual property rights, that a Party or one of its Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide or grant a license or sublicense to such intellectual property rights as provided for in this Agreement without violating the terms of any other agreement or other arrangement with or requiring any payment to any Third Party.
- 1.10 “**Field**” shall mean the treatment and/or prevention of COVID-19 caused by SARS-CoV-2.
- 1.11 “**Government**” or “**Governmental Authority**” is to be broadly interpreted and includes: (a) any national, federal, state, local, regional, or foreign government, or level, branch, or subdivision thereof; (b) any multinational or public international organization or authority; (c) any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power; (d) any court, tribunal, or governmental arbitrator or arbitral body; (e) any government-owned or -controlled institution or entity; (f) any enterprise or instrumentality performing a governmental function; and (g) any political party.
- 1.12 “**Government Official**” is to be broadly interpreted and includes: (a) any elected or appointed Government official (e.g., a legislator or a member of a ministry of health); (b) any employee or person acting for or on behalf of a Government, a Government department or agency, an institution or entity owned or controlled by a Government (e.g., a healthcare professional employed by a Government-owned or -controlled hospital, or a person serving on a healthcare committee that advises a Government), or an enterprise or instrumentality performing a governmental function; (c) any candidate for public office, or officer, employee, or person acting for or on behalf of a political party or candidate for public office; (d) an employee or person acting for or on behalf of a public international organization (e.g., the United Nations, the Red Cross, or the World Bank); (e) any member of a military or a royal or ruling family; and (f) any person otherwise categorized as a Government official under Applicable Law.
- 1.13 “**Improvements**” shall mean any (patentable or unpatentable) new or improved use, formulation, process, improvement, invention, development or finding related to the Compound, Product and/or the Licensed Product, or any (patentable or unpatentable) other pharmaceutical product containing or otherwise using Compound, or any further invention (patentable or unpatentable) that relates to the development, manufacture, formulation or use of the Licensed Products,

*Execution Version*

Products and/or Compound or that incorporate or are based on the Patents or Licensed Know-How Controlled by a Sublicensee or any of its Affiliates as of the Effective Date or at any time during the term of the Sublicense. For the avoidance of doubt, “Improvements” shall include any patent rights, Know-How or other intellectual property rights related to the Compound, Product and/or Licensed Product or that are necessary or useful for the development, manufacture and/or commercialization of Pfizer’s pharmaceutical product(s) containing or otherwise using the Compound, in each case that are Controlled by a Sublicensee or its Affiliates as of the Effective Date or at any time during the term of the Sublicense.

- 1.14 **“Know-How”** shall mean any and all confidential or proprietary information and materials, including discoveries, improvements, processes, methods, protocols, formulas, molecular constructs, reagents, assays, data, results, inventions, trade secrets, compositions of matter (including compounds), formulations, and findings, in each case, patentable or otherwise and including any copyrights therein.
- 1.15 **“Licensed Know-How”** shall mean all Know-How that (a) is Controlled by Pfizer or any of its Affiliates as of the Effective Date, (b) directly relates to the use of the Compound, Product or Licensed Product in the Field, and (c) is not in the public domain or otherwise generally known. For the avoidance of doubt, (i) Licensed Know-How shall not include any Know-How to the extent solely and directly related to any other Pfizer compound or to the extent related to the use of the Compound, Product or Licensed Product outside the Field and (ii) Licensed Know-How includes only that Know-How, designated by Pfizer in its sole discretion, necessary for the manufacture, registration and commercialization of the Compound and/or Licensed Product for use in the Field. For the avoidance of doubt, Licensed Know-How excludes any Know-How related to ritonavir that has been (either as of the Effective Date or at any time during the term of this Agreement) in-licensed by Pfizer from any Third Party.
- 1.16 **“Licensed Product”** shall mean a Product co-packaged and co-administered with the pharmaceutical product ritonavir, (a) where each dose to be administered to a patient consists of (i) Product containing three hundred (300) mg of Compound and (i) one hundred (100) mg of ritonavir and (b) that is labeled for the administration of two (2) doses per day for the course of treatment.

For purposes of calculating Net Sales, Licensed Product will refer to Licensed Product in final or bulk form when sold for Stockpiling purposes in a form other than final form. “Stockpiling” shall mean activities conducted by a Governmental Authority or Public Purchasers to address public health emergencies by purchasing and maintaining inventories of Licensed Product for distribution and use in responding to such emergencies. Stockpiling may apply to purchases of finished or bulk form pharmaceutical Licensed Products.

*Execution Version*

For the avoidance of doubt, any sale of Licensed Products in bulk form or for a Clinical Trial may only take place if permitted and approved in advanced in writing by Pfizer.

- 1.17 “**Non-Territory Patents**” shall mean any Patents, granted or pending, in any country that is not included in the Territory (as hereinafter defined). For the avoidance of doubt, to the extent international and regional patent applications are included in Patents, such international and regional patent applications are Non-Territory Patents only with respect to countries not included in the Territory.
- 1.18 “**Own Use**” shall mean the act of Commercialization and/or the act of registration of the Licensed Product, in each case, in the Territory for use in the Field.
- 1.19 “**Patents**” shall mean any unexpired letters patent or any patent applications as set forth in **Exhibit B** attached hereto, that are granted or pending, relating to the Compound and/or Licensed Product, including divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, pediatric exclusivity, and the like of any such patents and patent applications, and international (e.g., WIPO), regional (e.g., EP or EA), and foreign national equivalents of the foregoing, in each case to the extent Controlled by Pfizer or any of its Affiliates.
- 1.20 “**Pfizer Field**” shall mean the treatment and/or prevention of diseases caused by coronaviruses.
- 1.21 “**Pfizer Trademarks**” shall mean trademarks, service marks, logos, Internet domain names, trade dress, trade names, and corporate names, now existing or hereafter adopted or acquired, whether registered or unregistered, including without limitation any applications or registrations therefor, and all goodwill connected with the use thereof and symbolized thereby, that are owned, controlled or used by Pfizer or its Affiliates.
- 1.22 “**Product**” shall mean any pharmaceutical or biological composition or preparation (in any and all dosage forms, formulations and delivery modes) containing the Compound as its sole active ingredient, including any Improvements to the foregoing, (a) for sale or use by prescription, over-the-counter or any other method, or (b) for administration to, or use with, human patients in a human clinical trial (“**Clinical Trial**”) to the extent permitted pursuant to Section 3.3 of the Sublicense. For clarity, Product shall not include any pharmaceutical or biological composition or preparation containing both the Compound and another active ingredient in a single formulation.
- 1.23 “**Public Market**” shall mean, with respect to a country in the Territory, sales to the Government and Public Purchasers.
- 1.24 “**Public Purchasers**” shall mean with respect to a country in the Territory (a) the following organizations to the extent that they are not for profit organizations and

operate in such countries: (i) Non-Governmental Organizations to the extent that they are recognized by the applicable local government ministries from such country; (ii) UN-related organizations working for or in such country, including but not limited to UNDP and UNICEF; (iii) Not-for-profit organizations including without limitation, Médecins Sans Frontières, Save-the-Children, OXFAM and the International Committee of the Red Cross (ICRC) to the extent that they are recognized by the applicable local government ministries from such countries; (iv) programs funded by funding mechanisms, including without limitation, UNITAID, PEPFAR, USAID, and Global Fund; and agencies based outside the Territory to the extent that they are supporting implementation of the organizations described in clauses (i) through (iii) above locally in such country, and (b) nominally for profit procurement organizations but only to the extent that such procurements are supporting not-for-profit programs in such country as described in (a) of this definition within the Territory.

- 1.25 **“Retail”** shall mean sale, import, or export of the Licensed Product by the Sublicensee to another Sublicensee for the purpose of making the Licensed Product available in the Territory for such other Sublicensee’s Own Use.
- 1.26 **“Stringent Regulatory Authority” or “SRA”** shall mean an Agency which is: (a) a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before 23 October 2015); or (b) an ICH observer, being the European Free Trade Association, as represented by Swissmedic, and Health Canada (as before 23 October 2015); or (c) an Agency associated with an ICH member through a legally-binding, mutual recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 October 2015).
- 1.27 **“Sublicense”** shall mean an agreement in the form of Sublicense Agreement attached hereto as **Exhibit D** pursuant to which MPP grants to a Sublicensee a sublicense of the rights granted by Pfizer to MPP under Sections 2.1 and 2.2 of this Agreement.
- 1.28 **“Sublicensee”** shall mean a Third Party that (a) is engaged in the manufacture and sale in the Territory of pharmaceutical products, (b) meets all of the requirements set forth in Section 3 of this Agreement, including, without limitation, having demonstrated the willingness and capacity to (i) manufacture Licensed Product in a manner consistent with World Health Organization (**“WHO”**) prequalification standards and/or the standard of an SRA and (ii) make Licensed Product widely available in the Territory at terms that will facilitate access to Licensed Product for administration in the Territory to patients in the Field, and (c) is approved by Pfizer in writing prior to entering into a Sublicense with MPP.
- 1.29 **“Territory”** shall mean those countries set forth in **Exhibit C** attached hereto.

*Execution Version*

- 1.30 **“Territory Patents”** shall mean any Patents, granted or pending, in any country within the Territory. For the avoidance of doubt, to the extent international and regional patent applications are included in Patents, such international and regional patent applications are Territory Patents only with respect to countries within the Territory.
- 1.31 **“Third Party”** shall mean any person or entity other than Pfizer, MPP, and their respective Affiliates.
- 1.32 **“Valid Claim”** shall mean a claim of any issued and unexpired patent or pending patent application whose validity, enforceability, or patentability has not been affected by any of the following: (a) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or (b) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, Governmental Authority, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or unappealed within the time allowed for appeal.
- 1.33 **“Vend”** shall mean sale, import, or export of the Compound or Product by the Sublicensee to another Sublicensee for the purpose of manufacturing the Licensed Product for such other Sublicensee’s Own Use.
- 1.34 **Other Terms.** The definition of each of the following terms is set forth in the Section of this Agreement indicated below:

Defined Term	Section
Agreement	Preamble
BIS	4.8
Breach	4.9
breaching party	6.3
Claims	5.6
Clinical Trial	1.22
Combination	2.3
Confidential Information	7.1
Designated Officers	8.6(b)
Disclosing Party	7.1
EAR	4.8
Effective Date	Preamble
EUA	4.2
FCPA	4.9
Force Majeure	8.9
ICC	8.6(d)
Improvement License	4.5(a)
Losses	5.6
MPP	Preamble
non-breaching party	6.3

Defined Term	Section
OFAC	4.8
Officials	4.9
Option and ROFR	4.5(b)
Out-of-Field License	4.5(b)
Party or Parties	Preamble
Payment	4.9
Person	4.9
Pfizer	Preamble
Pfizer Consent Right	8.2
Pfizer Indemnitees	5.6
Proposed Assignment	4.3
Receiving Party	7.1
Sanctions	4.8
Sanctions Targets	4.8
Trade Control Laws	4.8
WHO	1.28

## 2. SCOPE OF LICENSE GRANT AND INTELLECTUAL PROPERTY MATTERS

- 2.1 License Grant within the Territory. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to MPP a non-exclusive, non-transferable, sublicensable (solely to Sublicensees through one tier), royalty-bearing right and license under the Territory Patents and Licensed Know-How to grant licenses to Sublicensees (solely by entering into Sublicenses with Sublicensees) for such Sublicensees solely to:
- (a) manufacture the Compound, Product and Licensed Product at a facility that is in the Territory (excluding any involvement of Sanctions Targets except as expressly permitted pursuant to Section 4.8 of this Agreement) and that is approved by an SRA or pre-qualified by the WHO;
  - (b) Commercialize the Licensed Product by itself or through its Affiliates in the Field in the Territory (excluding any involvement of Sanctions Targets except as expressly permitted pursuant to Section 4.8 of this Agreement);
  - (c) Retail the Licensed Product to other Sublicensees for such other Sublicensee's Own Use in the Territory;
  - (d) register the Licensed Product in the Field in the Territory for use by itself or, subject to Section 2.7 of the applicable Sublicense, through its Affiliates for the purposes described and pursuant to the rights granted in Section 2.1(b) or Section 2.1(e) of this Agreement;



- (e) sell the Licensed Product to Public Purchasers in the Territory for the sole purpose of enabling the Public Purchasers to supply the Licensed Product solely in the Territory for use in the Field; and
- (f) Vend the Compound and Product.

2.2 License Grant outside the Territory. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to MPP a non-exclusive, non-transferable, sublicensable (solely to Sublicensees through one tier), royalty-bearing right and license under the Non-Territory Patents and Licensed Know-How to grant licenses to Sublicensees (solely by entering into Sublicenses with Sublicensees) for Sublicensees to:

- (a) manufacture the Compound, Product and Licensed Product at a facility that is in a non-Territory country (excluding any involvement of Sanctions Targets except as expressly permitted pursuant to Section 4.8 of this Agreement) and that is approved by an SRA or pre-qualified by the WHO;
- (b) export Licensed Product manufactured (pursuant to the rights granted under Section 2.2(a) of this Agreement) outside the Territory to the Territory for its Own Use;
- (c) Retail Licensed Product manufactured (pursuant to the rights granted under Section 2.2(a) of this Agreement) outside the Territory in the Territory to other Sublicensees for their Own Use;
- (d) sell the Licensed Product to Public Purchasers outside of the Territory for the sole purpose of enabling such Public Purchasers to supply the Licensed Product in the Territory for use in the Field; and
- (e) Vend the Compound and Product.

2.3 License Restrictions. No rights are granted under this Agreement for any other purpose, and MPP agrees that it will not use the Patents or Licensed Know-How itself or grant sublicenses: (a) to entities or persons other than Sublicensees; (b) other than in the form of the Sublicense. MPP shall not permit any Sublicensee to grant any sublicenses of the license grants set forth in the Sublicense. No license or right is granted by implication or otherwise with respect to the Compound, Product and/or Licensed Product, except as expressly granted herein. Subject to the above and except as expressly permitted in this Agreement and the Sublicense, the Sublicensee shall not be entitled, directly or indirectly, to manufacture, use, Commercialize, Retail, Vend, register with Agencies, distribute, donate, offer for sale and/or sell the Compound, Product and/or the Licensed Product for any other purpose or in combination with any other substance, product, intermediate, and/or active pharmaceutical ingredient (whether co-packaged (other than with respect to Product, co-packaged with ritonavir in the form of Licensed Product), co-formulated or otherwise) (“**Combination**”) without the prior written approval of Pfizer in its sole

discretion, in which event any such approval shall be subject to separate terms and conditions to be negotiated.

- 2.4 No Waiver. For the avoidance of doubt, nothing in this Agreement or the Sublicenses shall be construed to prevent Sublicensees from engaging in activities inside or outside the Territory where such activities would not (a) infringe the Patents and/or any other intellectual property rights of Pfizer; (b) use or misappropriate Licensed Know-How; and/or (c) use or require the use of any of Pfizer's Confidential Information. Pfizer expressly reserves all its rights under the Patents, except as expressly set forth in this Agreement and Sublicenses, and under any additional patents and/or patent applications Controlled (either as of the Effective Date or at any time during the term of this Agreement) by Pfizer or its Affiliates. For the avoidance of doubt, it shall not be deemed a breach by a Sublicensee to supply Compound, Product or Licensed Product outside the Territory into a country where the Government of such country has, to the extent permitted by Applicable Law, granted or required to be granted to Sublicensee a compulsory license under the Patents relating to such Compound, Product or Licensed Product allowing for the importation of such Compound, Product or Licensed Product into such country, provided that (a) such Sublicensee's supply of Compound, Product or Licensed Product into such country is solely within the scope and geographic range of such compulsory license and only for the duration that such compulsory license is in effect and (b) such Sublicensee does not use or misappropriate Licensed Know-How and/or misappropriate, use or require the use of any of Pfizer's Confidential Information. Pfizer does not waive any applicable statutory and/or regulatory exclusivities owned or controlled by Pfizer, except as expressly set forth herein. Nothing in this Agreement or any Sublicense shall provide a right to Vend, donate, distribute, offer for sale or otherwise sell the Compound, Product or Licensed Product outside the Territory for further offer for sale, sale, donation or distribution of the Compound, Product or Licensed Product outside or for use outside the Territory.
- 2.5 Retained Rights. MPP acknowledges that the licenses granted pursuant to Sections 2.1 and 2.2 of this Agreement are non-exclusive and that Pfizer retains the right in its sole discretion to: (a) grant additional licenses or distribution rights for the Compound, Product and/or Licensed Product to Third Parties; and (b) make, use, import, offer for sale, sell and/or donate the Compound, Product and/or Licensed Product (or any other pharmaceutical product containing the Compound or Product) on its own behalf.
- 2.6 Regulatory Exclusivity Waivers. Pfizer shall provide, upon MPP's written request, a Sublicensee with regulatory exclusivity waivers to the extent required by the applicable Agencies in order for such Sublicensee to manufacture or sell Licensed Product in the Territory in accordance with the terms of the applicable Sublicense. MPP shall require that Sublicensees will agree not to seek any further regulatory exclusivity with respect to any of the Compound, Product or Licensed Product and to waive any such regulatory exclusivity if granted. For the avoidance of doubt, Pfizer will not be required to represent that any Licensed

Product is equivalent to any product containing Compound which is manufactured or sold by Pfizer, and no regulatory exclusivity waiver granted by Pfizer pursuant to this Section will be deemed as including any such representation.

- 2.7 No Other Licenses. Except as expressly set forth in this Agreement, Pfizer does not grant any license or other rights to MPP under any of its intellectual property rights (including, without limitation, patents, patent applications, Know-How or rights to any proprietary compounds or drug substances other than the Compound or for use of the Compound, Product or Licensed Product outside the Field or outside the Territory).
- 2.8 Trademarks. No rights in any Pfizer Trademarks are granted to MPP or Sublicensees under this Agreement. MPP shall require that Sublicensees do not, appropriate or otherwise use, apply to register or register any Pfizer Trademarks on or in connection with the Licensed Product in the Territory, including without limitation in connection with any sale, distribution, promotion, or marketing of the Licensed Product. MPP will require that a complete description of any trademark to be used by Sublicensees in connection with the sale of the Licensed Product in the Territory shall be submitted to MPP to be transmitted to Pfizer for Pfizer's written approval prior to use or filing an application to register such trademark. Such written approval shall be given within thirty (30) days following receipt by Pfizer from MPP of all the relevant documentation necessary to consider the Sublicensee's request. Such approval may be withheld if the subject trademark is determined by Pfizer, in its sole discretion, to be identical or confusingly similar to any Pfizer Trademark; provided, however, that any such approval shall not waive any rights of Pfizer or its Affiliates with respect to the Pfizer Trademarks. In addition to the foregoing, for the avoidance of doubt, MPP shall require that Sublicensees do not: (a) register or, in connection with the sale of any Licensed Product, use any trademark or trade name which is identical to or confusingly similar (as Pfizer shall determine in its sole discretion) to any Pfizer Trademark; (b) use trade dress, packaging (both internal and external) or labeling which is the same as or similar (as Pfizer shall determine in its sole discretion) to that of Pfizer or any Affiliate of Pfizer in connection with the sale of any Licensed Product; or (c) give the impression to the public, to physicians or to the trade that the Licensed Product is manufactured by, or in any way connected with, Pfizer or any of its Affiliates. Notwithstanding the foregoing, in reviewing and/or granting approval to any Sublicensee for use of any trademark in connection with the sale of any Licensed Product, Pfizer shall have no obligation to assess the availability or validity of, or the ability of the Sublicensee to use, the proposed trademark or whether the proposed trademark is the same or is similar to any trademark proposed to be used by and/or approved by Pfizer for use by any other Sublicensee in connection with the Compound or any Product or Licensed Product and Pfizer shall have no liability to MPP or any Sublicensee where a Sublicensee seeks to register or uses any trademark, logo or trade dress that is the same or similar to that used by another Sublicensee.

- 2.9 License Purpose. Notwithstanding anything to the contrary herein, MPP acknowledges that the licenses granted under this Section 2 are granted solely under and with respect to the Patents and Licensed Know-How for the sole purpose of final supply of the Licensed Products in the Territory.
- 2.10 Patent Prosecution; Enforcement and Defense. Pfizer shall have the sole right (but not the obligation) to file, prosecute and maintain the Patents in the Territory in Pfizer's name and at Pfizer's own cost and expense. Pfizer will have the sole right (but not the obligation), at its own expense, to control enforcement and defense of the Patents and Licensed Know-How against any Third Party infringement or action, as applicable. If MPP becomes aware of a possible infringement of the Patents by a Third Party in any country, MPP will notify Pfizer immediately so that Pfizer may decide, in its sole discretion, whether any action is necessary. For the avoidance of doubt, MPP shall ensure that each Sublicensee is aware of, and abides by, the notification requirements of this Section 2.10. In the event that Pfizer institutes an action at its expense against alleged Third Party infringers with respect to the Compound, Product or any Licensed Product, or takes action to defend the Patents, MPP agrees to cooperate in good faith with Pfizer in such action, upon the request of Pfizer and at a reasonable cost to be borne by Pfizer. Any recovery obtained by Pfizer as a result of such a proceeding or other action shall be retained by Pfizer.

### 3. **SUBLICENSES**

- 3.1 Form of Sublicense. MPP shall not grant sublicenses other than both (a) in the form of the Sublicense attached hereto as **Exhibit D** and (b) in accordance with this Section 3. Any purported Sublicense in any form other than the form attached hereto as **Exhibit D** shall be deemed null and void and of no effect.
- 3.2 Amendments and Waivers. MPP shall not amend, modify, supplement or otherwise alter the terms and conditions of the form of Sublicense attached hereto as **Exhibit D** or any executed Sublicense, without the express prior written consent of Pfizer. MPP shall not waive any obligations or liabilities of a Sublicensee under a Sublicense without the express prior written consent of Pfizer.
- 3.3 Identification of Sublicensees. Subject to the terms and conditions of this Agreement, including, without limitation, Section 3.4, MPP may grant sublicenses (solely by entering into Sublicenses) to any entity (a) with demonstrated commitment, ability and readiness to develop, manufacture and Commercialize Licensed Product and/or Compound in accordance with the Sublicense to be granted and (b) satisfying certain other criteria to be jointly established by the Parties. The Parties agree to meet and confer promptly following the Effective Date to agree on the criteria by which MPP will make such assessment.
- 3.4 Pfizer's consent. Pfizer shall have the right of approval over each proposed Sublicensee, such approval not to be unreasonably withheld. Pfizer's response

*Execution Version*

will be provided within thirty (30) Business Days following MPP's initial written notice of intent to sign a Sublicense with a proposed Sublicensee, such notice to include reasonably detailed information regarding the proposed Sublicensee to permit Pfizer to assess the proposed Sublicensee's compliance with the criteria to be established pursuant to Section 3.3 of this Agreement; provided, however, that Pfizer shall have the right to extend such review period for an additional fifteen (15) Business Days. In the event that Pfizer does not provide consent, Pfizer shall discuss with MPP the reasons for Pfizer's withholding of consent; provided, however, that such discussion, including such reasons for withholding consent, shall be the Confidential Information of Pfizer and MPP shall not disclose such reasons to a potential Sublicensee or any other person without Pfizer's express prior written consent. MPP shall provide to Pfizer a complete and accurate executed copy of each Sublicense and each amendment thereto within at least ten (10) Business Days following execution of such Sublicense or amendment, as applicable, and in all cases prior to making such Sublicense or amendment, as applicable, publicly available.

- 3.5 Insurance. MPP shall cause Sublicensees to purchase and maintain appropriate insurance as per the terms in the form of Sublicense attached hereto as **Exhibit D**.
- 3.6 Data Package. Following the Effective Date, Pfizer shall assemble a discrete data package related to the Compound, the contents of which shall be determined by Pfizer in its sole discretion. A Sublicensee shall submit any request for access to the data package to MPP in writing. MPP shall collect relevant access information, as determined by Pfizer, from such Sublicensee to enable access to the data package and submit such information to Pfizer, following which Pfizer shall make the data package available to such Sublicensee. MPP acknowledges that such data package is and shall be treated by MPP and each Sublicensee as Pfizer's Confidential Information. Pfizer shall also develop a high-level summary of topics included in the data package, which MPP may provide to a Sublicensee or potential Sublicensee upon such Sublicensee's or potential Sublicensee's written request, provided that such summary shall not create any obligation on the part of Pfizer to include any specific piece of information in the data package. Pfizer shall not be required to provide any other technical support or technical assistance to a Sublicensee for any reason.
- 3.7 Third Party Beneficiary Rights under the Sublicense. Pfizer shall be a third party beneficiary of each Sublicense and shall have the right to exercise any rights of MPP under the Sublicense, including, without limitation, any right that MPP may have to terminate a Sublicense.

#### **4. MPP OBLIGATIONS**

- 4.1 Monitoring of Compliance. MPP agrees to monitor compliance with each Sublicense by each Sublicensee, as follows:

*Execution Version*

- (a) reviewing with all reasonable skill and care any reports provided to MPP by the Sublicensee under the Sublicense; and
- (b) within thirty (30) days following the expiration of the ten (10) Business Day period referred to in Section 11.2 of the Sublicense, assessing in relation to each Sublicensee whether the supplies of Licensed Products made in the relevant Calendar Quarter were made in accordance with the terms of the Sublicense, and if they were not, reporting the outcome of such assessment to Pfizer.

4.2 Reports. For the period beginning from the Effective Date, within thirty (30) Business Days following the end of each Calendar Quarter, MPP will submit to Pfizer a quarterly progress report covering Sublicensees' activities related to the development and testing of all Licensed Products, Products and/or Compound (as permitted and to the extent applicable) and the obtaining of necessary governmental approvals, including, but not limited to (and to the extent applicable and permitted), each Sublicensee's (a) Licensed Products, Products and/or Compound in its development pipeline, (b) status of development of each Licensed Product, Product and/or Compound in development, (c) regulatory filing plan for WHO Prequalification Programme and/or an SRA, including where applicable any local regulatory filings, for each Licensed Product, (d) a list of Agencies, including as applicable the FDA, WHO and authorities in the countries within the Territory for which such regulatory approvals or authorizations have been filed and/or obtained for any Licensed Product, (e) summary of work completed and in progress, (f) current schedule of anticipated events and milestones, (g) anticipated market introduction dates, (h) all bioequivalence data generated by or on behalf of such Sublicensee related to Product or Licensed Product, and (i) other activities, if applicable. Pfizer agrees that information contained in quarterly and other such reports shall be the confidential information of the respective Sublicensee and subject to Pfizer's confidentiality obligations pursuant to Section 7 of this Agreement. MPP will also report to Pfizer the date of first commercial sale of each Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an emergency use authorization ("EUA") or other Agency approval or authorization, within five (5) Business Days thereafter. After the first sale anywhere in the Territory, MPP will make quarterly royalty reports to Pfizer within thirty (30) days after the end of each Agreement Quarter. Each such royalty report will include at least the requirements as further stated in Appendix 4 of the applicable Sublicense and in accordance with applicable competition laws. For the avoidance of doubt, royalty reports shall include sales for which no royalty payment may be due and payable. If no sales had occurred during the reporting period, MPP shall include a statement to this effect in the royalty report for that period. MPP shall also provide the names and addresses of any new Sublicensees for the reported Calendar Quarter. As between the Parties, the reports and all information contained therein (including, but not limited to, the royalty payments) shall be treated as the Confidential Information of Pfizer.

- 4.3 Registration Assignments. MPP shall prohibit Sublicensees from transferring, assigning, or otherwise conveying any of the authorizations, registrations, or permits related to the Licensed Product, as set forth in the applicable Sublicense to any Third Party (“**Proposed Assignment**”). Where there is a Proposed Assignment, Pfizer shall be immediately notified in writing and, at its sole discretion, decide whether to approve such Proposed Assignment.
- 4.4 Pharmacovigilance. MPP shall cause Sublicensees to agree to cooperate with Pfizer in fulfilling any pharmacovigilance reporting responsibilities that Pfizer may have under Applicable Law in areas where Pfizer is a marketing authorization or EUA holder (or equivalent) and as arising out of this Agreement; provided Sublicensees must be responsible for fulfilling all pharmacovigilance activities pursuant to the local regulations and requirements for the Licensed Products sold or distributed by or on behalf of such Sublicensees in the Territory. If MPP or any Sublicensee becomes aware of any adverse reaction relating to Licensed Products in connection with this Agreement or a Sublicense, MPP or the relevant Sublicensee shall inform Pfizer within twenty-four (24) hours of its becoming aware and cooperate with Pfizer in fulfilling Pfizer’s reporting responsibilities under Applicable Law.
- 4.5 Improvements.
- (a) MPP shall require Sublicensees to disclose promptly to Pfizer in English, without charge, any Improvements. As to any such Improvements, MPP shall require that Sublicensees grant to Pfizer, its Affiliates, and MPP a perpetual, irrevocable, worldwide, non-exclusive, transferable and fully paid-up license, with the right to grant sublicenses through multiple tiers, under any and all Improvements (the “**Improvement License**”) for any and all purposes in the Pfizer Field, including the rights to use, have used, develop, have developed, manufacture, have manufactured, commercialize and have commercialized, offer for sale, sell, have sold or donate the Compound, Product and/or Licensed Product or any other product containing the Compound in the Pfizer Field. For the avoidance of doubt, the Improvement License shall not affect the Sublicensee’s ownership of any Improvements to the Licensed Product. MPP shall not sublicense the Improvement License to any Third Party or to another Sublicensee without the prior written consent of the Sublicensee and Pfizer.
- (b) MPP shall require that Sublicensees grant to Pfizer and its Affiliates a perpetual, irrevocable, worldwide, non-exclusive, transferable and fully paid-up license, with the right to grant sublicenses through multiple tiers, under any and all Improvements for any use outside the Pfizer Field (the “**Out-of-Field License**”). MPP shall further require that each Sublicensee grants to Pfizer and its Affiliates an option and right of first refusal to obtain a sole, sublicensable, worldwide license under any and all Improvements for any use outside the Field on reasonable financial terms to be negotiated by Pfizer and such Sublicensee (the “**Option and**

**ROFR**”). For the avoidance of doubt, the Out-of-Field License and Option and ROFR shall not affect the Sublicensee’s ownership of any Improvements to the Licensed Product.

- 4.6 Notification of Breach. If MPP becomes aware of any act or omission of a Sublicensee which constitutes a breach of the relevant Sublicense, MPP shall immediately notify Pfizer and (a) if the breach is capable of correction and does not give rise to an immediate right of termination under the Sublicense, direct the relevant Sublicensee in writing to cure the breach with copy to Pfizer; and (b) if the breach remains uncured at the end of the period specified in Section 12.2 of the Sublicense, or if there are otherwise grounds for termination under the Sublicense, terminate the relevant Sublicense in accordance with its terms, either by MPP’s decision or upon Pfizer’s request.
- 4.7 Termination for Breach of License Grant. Notwithstanding the above and for the avoidance of doubt, any breach of the scope of grant by a Sublicensee shall constitute a material breach. Pfizer shall, at its sole discretion and without further liability, have the right to direct MPP to terminate the Sublicense. Such termination shall be without prejudice to other rights or remedies available to Pfizer under this Agreement, the relevant Sublicense or at law.
- 4.8 Trade Control Laws. The Parties shall comply with all applicable economic sanctions and export control laws in the performance of this Agreement, including without limitation the sanctions programs administered by the U.S. Department of Treasury’s Office of Foreign Assets Control (“**OFAC**”) and the Export Administration Regulations (“**EAR**”) administered by the U.S. Department of Commerce’s Bureau of Industry and Security (“**BIS**”) (collectively “**Trade Control Laws**”). MPP represents that neither MPP nor, to the knowledge of MPP, any director, officer, employee, or agent of MPP, is an individual or entity (“**Person**”) that is, or is fifty percent (50%) or more owned or controlled by Persons that are: (a) the target of any sanctions administered or enforced by the U.S. Government, including by OFAC, or by the governments of Switzerland, the EU, or the United Kingdom (“**Sanctions**”) or listed on any denied party lists maintained by OFAC, BIS or on the European Union’s Consolidated List of Persons, Groups and Entities Subject to EU Financial Sanctions, or (b) located, organized or resident in a country or territory that is, or whose government is, the target of Sanctions (including, without limitation, Cuba, Iran, North Korea, Crimea, Venezuela, and Syria) ((a) and (b) collectively, “**Sanctions Targets**”).

MPP further warrants that in relation to this Agreement it will not, directly or indirectly, sublicense, use, transfer, lend, contribute or otherwise make available any rights (including intellectual property rights) to any Sanctions Target, nor to any Person to engage in any activities or business of or with any Sanctions Target or in any country or territory, that, at the time of such transfer or other transaction, is, or whose Government is, the target of Sanctions (including, for the avoidance of doubt, any country listed in **Exhibit C**) without prior written approval from Pfizer. MPP covenants that it shall notify Pfizer in writing immediately if any of



*Execution Version*

the preceding representations and warranties becomes incorrect during the term of this Agreement. In case of an inaccuracy in, or breach of, the representations, warranties or covenants in this Section 4.8 during the term of this Agreement, Pfizer shall be entitled to terminate this Agreement immediately and without penalty to Pfizer.

Notwithstanding anything to the contrary in this Agreement, including **Exhibit C**, the Parties acknowledge that the grant of any rights or Know-How by Pfizer under this Agreement relating to the Compound, Product or Licensed Product for, in, or to the Sanctions Targets require prior authorization, in the form of general licenses, specific licenses, and/or other authorizations, from OFAC and/or BIS. Accordingly, nothing in this Agreement, including **Exhibit C**, shall be construed as a grant of rights or Know-How under this Agreement with respect to Sanctions Targets. MPP shall and shall ensure that the Sublicensees shall, to the extent required, comply with applicable Trade Control Laws and shall not cause Pfizer to violate any applicable Trade Control Laws.

#### 4.9 Ethical Business Practices.

By signing this Agreement, MPP agrees to conduct the business contemplated herein in a manner which is consistent with both Applicable Law and good business ethics.

Specifically, MPP warrants that none of the employees, agents, officers, or other members of the management of MPP or its Affiliates or permitted assignees/transferees are or will become during the term of this Agreement Government Officials having governmental authority to make or participate in any decisions regarding the Licensed Product in the Territory. MPP has not and shall not make any payment or promise of payment, either directly or indirectly, of money or any other thing of value, including, but not limited to, any compensation derived from this Agreement (hereinafter collectively referred to as a “**Payment**”), to Government Officials or representatives of other businesses or persons acting on behalf of any of the foregoing where such Payment would constitute a violation of any Applicable Law. In addition, regardless of legality, MPP has not and shall not make any Payment either directly or indirectly to Government Officials if such Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of MPP’s or Pfizer’s business.

Pfizer and MPP shall comply with, and will not cause each other and their Affiliates, associates, directors, officers, shareholders, employees, representatives, or agents worldwide to be in violation with any applicable anti-corruption law or regulation and notably without limiting the foregoing to any provision of the United States Foreign Corrupt Practices Act (the “**FCPA**”) and U.K. Bribery Act 2010. In light of the aforementioned, Pfizer and MPP shall not, directly or indirectly, pay any money to, or offer or give anything of value to, any Government Official in order to obtain or retain business or to secure any

*Execution Version*

commercial or financial advantage for Pfizer or MPP or any of their respective Affiliates. Pfizer and MPP undertake not to bribe Government Officials or any private companies or individuals, bribes having the following definition: offering, promising, or giving a financial or other advantage to another person where: (a) it is intended to bring about the improper performance of a relevant function or activity, or to reward such “Improper Performance” (as that term is used in the FCPA); or (b) acceptance of the advantage offered, promised or given in itself constitutes improper performance of a relevant function or activity.

MPP will maintain proper and accurate books, records, and accounts which accurately and fairly reflect any and all payments made, expenses incurred and assets disposed of in connection with its performance of this Agreement, and will maintain an internal accounting controls system to ensure the proper authorization, recording and reporting of all transactions and to provide reasonable assurances that any breaches of this Section 4.9 will be prevented, detected and deterred. MPP grants Pfizer the right, through the engagement of an independent, internationally-recognized accounting firm and with reasonable notice, to: (i) inspect and audit the performance of, and compliance with, this Agreement and Applicable Law; and (ii) inspect and audit all documents and other records relating to the performance of this Agreement. MPP will cooperate with and provide all reasonable assistance to Pfizer, its officers, employees, agents, advisors, representatives or contractors exercising Pfizer’s rights under this paragraph. Pfizer will provide MPP with a commercially reasonable period of notice of the proposed audit; provided, however, that dispute as to such notice shall not limit MPP’s obligations under this paragraph. The Parties agree that such audits will not be conducted more than once in any twelve (12)-month period, unless the prior audit has shown evidence of the failure of MPP or a Sublicensee to perform in compliance with this Agreement or with Applicable Law.

MPP further acknowledges that no employee of Pfizer or its Affiliates shall have the authority to give any direction, either written or oral, relating to any Payment by MPP or its agents, employees, officers, subcontractors, sublicensees (i.e., Sublicensees) or Affiliates, to any Third Party in violation of this Agreement.

Pfizer may, in the event that it determines that MPP has breached any provision of this Section 4.9, provide written notice to MPP of its intention to terminate this Agreement, along with any evidence supporting its claim of breach (“**Breach**”) to the extent that it is possible to provide. The Parties will discuss any mitigation plans to the Breach but in the event that no consensus can be reached, Pfizer shall have the sole right to terminate this Agreement. These measures are in addition and without prejudice to any other remedies that may be available.

In addition to all other remedies and indemnities provided for in this Agreement, MPP and its Affiliates shall indemnify and hold Pfizer and any of its Affiliates harmless from and against any and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that

may arise by reason of the acts or omissions of MPP or Third Parties acting on MPP's behalf which would constitute a violation of this Section 4.9.

## **5. REPRESENTATIONS, WARRANTIES, COVENANTS, INDEMNIFICATION AND LIABILITY**

5.1 Mutual Representations and Warranties. MPP and Pfizer each represents and warrants that:

- (a) it is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
- (b) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof; and
- (c) the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a Party or by which it is bound, nor violate any law or regulation of any Governmental Authority having jurisdiction over such Party.

5.2 Additional Pfizer Representations and Warranties. Pfizer represents and warrants that as of the Effective Date:

- (a) it owns the entire right, title, and interest in, or otherwise has the right to grant the licenses and rights granted to MPP herein within the scope of the Patents and the Licensed Know-How, and Pfizer and its Affiliates have not, and shall not, grant any rights under the Patents or Licensed Know-How that conflict with such licenses and rights or that would otherwise prevent MPP from exercising its rights or performing its obligations hereunder;
- (b) to the extent the Patents have been granted, Pfizer has no knowledge of any pending or threatened opposition, interference, or litigation proceedings; and
- (c) it has not, nor to its knowledge, has any Third Party acting under authority of Pfizer, made an untrue statement of a material fact to any Agency in the Territory with respect to any Licensed Product manufactured by or on behalf of Pfizer, or knowingly failed to disclose a material fact required to be disclosed to any Agency in the Territory with respect to any such Licensed Product, or knowingly failed to disclose a material fact required to be disclosed to any Agency in the Territory with respect to such Licensed Product.

5.3 Additional MPP Representations and Warranties. MPP represents and warrants that it is not, and it shall not employ or otherwise use in any capacity the services of any person or entity in performing any activities under this Agreement that is, a Sanctions Target, or is debarred by any Agency or the subject of debarment proceedings by any Agency). MPP shall notify Pfizer, in writing, immediately if any such sanctions or debarment occurs, comes to its attention or is threatened, and shall, with respect to any person or entity so sanctioned or debarred, promptly remove such person or entity from performing any further activities under this Agreement, as applicable.

5.4 Law Compliance

(a) General. MPP covenants and agrees that it shall perform all activities under this Agreement in accordance with all Applicable Law, including any US, EU, Swiss, or other anti-corruption, anti-competition, sanctions and export control laws and regulations that may apply. MPP further agrees that it shall not export, re-export, transfer, transmit, or release (including to a foreign national within the United States and Germany) any goods, materials, software, or technology (including technical data) without first obtaining all necessary authorizations from the relevant Governmental Authorities. Notwithstanding anything herein to the contrary, any delay or failure to perform any part of this Agreement by either Party resulting from a denial, delay, or withdrawal of any required export authorization shall not constitute a breach of this Agreement nor expose either Party to liability hereunder.

(b) Conflicts. Neither Party shall be required to take any action or perform any obligation under this Agreement to the extent that such action or obligation is in direct conflict with, or penalizable under, any Applicable Law.

5.5 DISCLAIMER: EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, PFIZER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE PATENTS OR ANY LICENSE GRANTED BY PFIZER HEREUNDER, OR WITH RESPECT TO THE COMPOUND, PRODUCT OR THE LICENSED PRODUCTS, OR ANY OTHER MATTER. FURTHERMORE, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE PATENTS IS VALID OR ENFORCEABLE OR THAT THE MPP'S OR SUBLICENSEE(S)'S USE OF THE PATENTS, LICENSED KNOW-HOW COMPOUND, PRODUCT OR LICENSED PRODUCT AS CONTEMPLATED HEREUNDER WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. PFIZER ALSO MAKES NO

REPRESENTATION OR WARRANTY THAT MPP'S OR SUBLICENSEE(S)'S USE OF THE COMPOUND, PRODUCT OR LICENSED PRODUCT WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS (OTHER THAN THE PATENTS AND LICENSED KNOW-HOW) OF PFIZER OR ITS AFFILIATES. PFIZER ALSO DOES NOT GIVE ANY WARRANTY, EXPRESS OR IMPLIED, WITH REGARD TO THE SAFETY OR EFFICACY OF THE COMPOUND, PRODUCT OR THE LICENSED PRODUCT AND IT SHALL BE THE SOLE RESPONSIBILITY OF THE SUBLICENSEES TO ENSURE SUCH SAFETY OR EFFICACY.

- 5.6 Indemnity. MPP shall jointly and severally indemnify, hold harmless and defend Pfizer, inventors of any patents and patent applications within the Patents, its and their respective Affiliates, Third Parties to whom Pfizer or its Affiliates may directly or indirectly owe an indemnity, and each of their respective directors, officers, employees, contractors and agents (collectively, the **"Pfizer Indemnitees"**), from and against any and all claims, demands, actions and proceedings (whether criminal or civil or in contract, tort or otherwise) (**"Claims"**) for losses, damages, liabilities, costs and expenses (including, without limitation, attorneys' fees, witness fees, damages, judgments, fines, and amounts paid in settlement), and any amounts a Pfizer Indemnitee becomes legally obligated to pay (**"Losses"**), directly or indirectly, arising out of, resulting from or related to: (a) the development, manufacture, use or sale of the Compound, Product or any Licensed Product by MPP, any Sublicensee and its or their Affiliates and its or their respective directors, officers, employees, contractors and agents (including any product liability, liability for death, illness, personal injury, improper business practice or any other statutory liability or any other liability under any law or regulation to the extent arising or resulting therefrom), (b) any breach of the terms and conditions of this Agreement or the applicable Sublicense by MPP, any Sublicensee, its or their Affiliates and their respective directors, officers, employees, contractors and agents, (c) any negligence, recklessness or willful misconduct or wrongful intentional omissions of MPP, any Sublicensee, its or their Affiliates and their respective directors, officers, employees, contractors and agents, (d) violation of Applicable Law by MPP, any Sublicensee, its or their Affiliates and their respective directors, officers, employees, contractors and agents, or (e) the alleged or actual infringement or misappropriation of any Third Party's intellectual property rights; provided, however, that the indemnification obligations set forth herein shall not apply to the extent such Losses directly result from the willful misconduct of the Pfizer Indemnitees.

In connection with any Claim for which Pfizer seeks indemnification from MPP pursuant to this Agreement, Pfizer shall: (i) give MPP prompt written notice of the Claim, provided that failure to provide such notice shall not relieve MPP from its liability or obligation hereunder except to the extent of any material prejudice as a direct result of such failure; (ii) cooperate with MPP, at MPP's expense, in connection with the defense and settlement of the Claim; and (iii) permit MPP to

control the defense and settlement of the Claim, provided that MPP may not settle the Claim without Pfizer's prior written consent in the event that such settlement admits wrongdoing on the part of Pfizer, admits invalidity, unenforceability or non-infringement of any Patent, imposes any financial obligations on Pfizer or otherwise materially adversely impacts Pfizer's rights or obligations. Further, Pfizer shall have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and its own expense. Notwithstanding the foregoing, Pfizer, directly or through any of its Affiliates, may elect to assume control of the defense of a Claim at any time if, in Pfizer's sole discretion: (A) MPP fails to timely assume the defense of or reasonably defend such Claim in good faith to the satisfaction of Pfizer or its Affiliates; or (B) Pfizer or its Affiliates believes in good faith that a bona fide conflict exists between Indemnitee(s) and MPP with respect to such Claim. Upon written notice of such election, Pfizer shall have the right to assume control of such defense (directly or through either one of its Affiliate), and MPP shall pay (as incurred and on demand), all Losses, including, without limitation, the reasonable attorneys' fees and other expenses incurred by Indemnitee(s), in connection with the Claim. In all events, MPP shall cooperate with Indemnitee(s) in the defense, settlement or compromise of the Indemnified Claim.

Costs and expenses, including, without limitation, fees and disbursements of counsel, incurred by the Indemnitee(s) in connection with any Claim shall be reimbursed on a quarterly basis by MPP, without prejudice to MPP's right to refund in the event that MPP is ultimately held in a final, non-appealable judgment or award to be not obligated to indemnify the Indemnitee(s).

- 5.7 PFIZER LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, IN NO EVENT SHALL PFIZER BE LIABLE TO MPP OR ANY SUBLICENSEE FOR ANY DAMAGES, WHETHER CHARACTERIZED AS DIRECT OR INDIRECT DAMAGES, INCLUDING, BUT NOT LIMITED TO, ANY SPECIAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF BUSINESS OR PROFITS), RELATED TO THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, AND PFIZER SHALL NOT HAVE ANY RESPONSIBILITIES OR LIABILITIES WHATSOEVER WITH RESPECT TO PATENTS, LICENSED KNOW-HOW, COMPOUND, PRODUCT OR LICENSED PRODUCT, EVEN IF, IN ANY SUCH CASE, MPP IS ADVISED OF THE POSSIBILITY OF SUCH CLAIMS OR DEMANDS, REGARDLESS OF THE FORM OF ACTION OR LEGAL THEORY, WHETHER UNDER CONTRACT LAW, TORT LAW (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE), STRICT LIABILITY, STATUTE, WARRANTY OR OTHERWISE. IN NO INSTANCE SHALL PFIZER AND ITS AFFILIATES BE LIABLE TO MPP (WHETHER ARISING IN WARRANTY, TORT (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE), CONTRACT, STRICT LIABILITY OR OTHERWISE) FOR ANY LIABILITIES OF MPP TO ANY THIRD PARTY, INCLUDING, WITHOUT LIMITATION, THROUGH

CONTRIBUTION, INDEMNITY, OR FOR ANY CLAIM FOR WHICH MPP WOULD HAVE TO INDEMNIFY PFIZER IF THAT CLAIM WERE BROUGHT DIRECTLY AGAINST PFIZER.

## **6. TERM AND TERMINATION**

- 6.1 Term. Unless otherwise terminated by the operation of law or by acts of the Parties in accordance with the terms of this Agreement, this Agreement will be in force from the Effective Date and will remain in effect until the later of (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in each country of sale (within the Territory) or manufacture of a Licensed Product; or (b) expiration of the last regulatory exclusivity for a Licensed Product in a country of sale within the Territory.
- 6.2 Pfizer Termination. This Agreement may be terminated by Pfizer upon written notice to MPP with immediate effect in the event of any of the following:
- (a) prior to obtaining US FDA approval, Pfizer stops development of the Compound, Product or Licensed Product in the Field;
  - (b) Pfizer no longer retains the rights necessary to sell the Licensed Product in the Territory or to license such rights to Third Parties;
  - (c) Pfizer determines at its sole discretion that the continued sale of such Licensed Product would not be medically appropriate or would otherwise harm Pfizer's business reputation;
  - (d) Pfizer does not file an application for emergency use authorization or regulatory approval of the Licensed Product with any Agency by December 31, 2021, or such other later dates as Pfizer may determine in its sole discretion;
  - (e) MPP has not entered into a Sublicense with at least one (1) Sublicensee within six (6) months from the execution of this Agreement;
  - (f) Pfizer does not get any regulatory authorization or approval for the Licensed Product within twelve (12) months of filing either an application for an emergency use authorization or an application for marketing approval; or
  - (g) MPP is in breach of Section 4.8 or Section 4.9 of this Agreement.
- 6.3 Termination for Breach. A Party ("**non-breaching party**") shall have the right to terminate this Agreement in the event that the other Party ("**breaching party**") is in material breach of any of its material obligations under this Agreement. The non-breaching party shall provide written notice to the breaching party. The breaching party shall have a period of thirty (30) days after such written notice to cure such breach, or to provide a timeline to cure such breach to the satisfaction of

the non-breaching party. If such breach is not cured within the thirty (30)-day period or in accordance with the timeline, this Agreement shall automatically terminate thirty (30) days after the date of a written notice of termination by the non-breaching party. Any termination pursuant to this Section 6.3 will not (1) relieve either Party of any obligation or liability accrued as of the effective date of termination; (2) impair any accrued rights of either Party; or (3) rescind anything done by either Party hereunder prior to the time of such termination becoming effective.

- 6.4 Insolvency. Either Party may terminate this Agreement in the event that the other Party becomes insolvent, makes an assignment to the benefit of creditors, or has a petition in bankruptcy filed for or against it.
- 6.5 Effect of Termination. In the event that this Agreement is terminated other than under Section 6.1 of this Agreement, (a) all rights and licenses granted to MPP under Sections 2.1 and 2.2 of this Agreement shall terminate and MPP will cease all use of the Patents and the Licensed Know-How, (b) each Sublicense then in effect and good standing will be automatically converted into direct licenses between Pfizer and the applicable Sublicensee, provided (i) such Sublicensee is not in breach of the Sublicense, (ii) Pfizer reserves its rights to terminate the license (so converted from such Sublicense) on the same grounds as those having led to termination of this Agreement or pursuant to any rights of termination specified in such Sublicense and (iii) the terms of the Sublicense shall be no more onerous upon Pfizer than the terms of the Pfizer-MPP Agreement, and (c) neither Party will be relieved of any obligation that accrued prior to the effective date of such termination. For the avoidance of doubt, if the expiration or termination of this Agreement results from either of Section 6.1 or Section 6.2 of this Agreement, the Sublicenses will automatically be terminated.
- 6.6 Survival. Sections 1, 2.3, 2.7, 2.8 (with respect to liability as set forth in the last sentence), 2.10, 3.2, 3.5 (as applicable to Sublicensees' surviving obligations under Section 10 of the Sublicense), 3.7, 4.4, 4.5, 5.5, 5.6, 5.7, 6.5, 7, 8 and this Section 6.6 shall survive termination or expiration of this Agreement.

## **7. CONFIDENTIALITY AND PUBLICATIONS**

- 7.1 Confidential Information. All technology, Know-How, business information, quarterly reports, correspondence, or any other confidential information disclosed by one Party (the “**Disclosing Party**”) to the other Party (the “**Receiving Party**”) hereunder (“**Confidential Information**”) shall: (a) be used solely and exclusively by Receiving Party and in a manner consistent with the rights granted hereunder and the purposes of this Agreement as stated in the preamble and recitals hereto; (b) maintained in confidence by the Receiving Party; and (c) shall not be disclosed to any Third Party or used for any purpose except to exercise its rights and perform its obligations under this Agreement without the prior written consent of the Disclosing Party, except to the extent that the Receiving Party can demonstrate by competent written evidence that such information: (i) is known



by the Receiving Party at the time of its receipt and, not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party's business records; (ii) is in the public domain other than as a result of any breach of this Agreement by the Receiving Party; (iii) is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party who may lawfully do so; or (iv) is independently discovered or developed by the Receiving Party without the use of, or reference to, Confidential Information of the Disclosing Party, as documented by the Receiving Party's business records. For the avoidance of doubt, wherever Pfizer has a contractual obligation towards a Third Party to disclose information regarding the Licensed Product, Product or Compound, Pfizer may disclose Confidential Information to that Third Party under obligations of confidentiality no less stringent than contained herein.

Within thirty (30) days after any expiration or termination of this Agreement, the Receiving Party shall destroy (and certify to the Disclosing Party such destruction) or return all Confidential Information provided by the Disclosing Party except as otherwise set forth in this Agreement. One (1) copy of the Disclosing Party's Confidential Information may be retained in the Receiving Party's files solely for archival purposes as a means of determining any continuing or surviving obligations under this Agreement. The confidentiality obligations under this Agreement shall survive this Agreement for a period of ten (10) years.

- 7.2 Publicity. The Parties will fully cooperate and work together to counter any misinformation related to the Compound, Product and Licensed Product and the Field. Each Party shall seek the other's prior written approval of each press release or public announcement concerning or characterizing the grant, scope or terms of this license prior to such press release or other publication being made; provided, however, that neither Party shall be required to seek the other Party's consent to or approval of any subsequent statements or press releases solely to the extent that such statements or press releases are accurate, factual, not misleading, do not include any information that was not included in a previously approved press release or public announcement in accordance with this Section 7.2, and are consistent with the confidentiality obligations required of either Party. Each Party will cause their employees, contractors, management team and the members of their Board of Directors (or its equivalent) to comply with the terms and conditions of this Section 7.2.

## **8. MISCELLANEOUS**

- 8.1 Agency. Neither Party is, nor will be deemed to be, an employee, agent, or representative of the other Party for any purpose. Each Party is an independent contractor, not an employee or partner of the other Party. Neither Party shall have the authority to nor shall, explicitly or implicitly, represent that they have the authority to speak for, represent, or obligate the other Party in any way without prior written authority from the other Party.

- 8.2 Entire Understanding. This Agreement embodies the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof. In each instance under this Agreement where Pfizer's consent, approval, permission, acquiescence or other form of acceptance is required ("**Pfizer Consent Right**"), it shall be read and understood to mean that Pfizer may withhold such Pfizer Consent Right at its sole and absolute discretion unless a contrary standard is expressly stated therein with respect to such Pfizer Consent Right.
- 8.3 Severability. The Parties hereby expressly state that it is not their intention to violate any applicable rule, law, or regulation. If any of the provisions of this Agreement are held to be void or unenforceable with regard to any particular country by a court of competent jurisdiction, then, to the extent possible, such void or unenforceable provision shall be replaced by a valid and enforceable provision which will achieve as far as possible the economic business intentions of the Parties. The provisions held to be void or unenforceable shall remain, however, in full force and effect with regard to all other countries. All other provisions of this Agreement shall remain in full force and effect.
- 8.4 Notices
- (a) Any legal notice or other communication to be given under this Agreement, unless otherwise specified, shall be in writing and shall be deemed to have been provided when delivered to the addressee at the address listed below (i) on the date of delivery if delivered in person or (ii) one day after receipt if sent by a reputable international courier service:

**In the case of Pfizer:**

PF PRISM Holdings B.V.  
C/O Pfizer Inc.  
235 East 42<sup>nd</sup> Street  
New York, NY 10017  
USA  
Attention: Douglas M. Lankler  
Bryan A. Supran  
Email:

with copies to each of the following:

Pfizer Inc.  
235 East 42<sup>nd</sup> Street  
New York, NY 10017  
USA  
Attention: Ravi Pherwani

Pfizer Legal Department  
Email:

**In the case of MPP:**

Medicines Patent Pool  
Rue de Varembé 7  
Geneva 1202  
Switzerland

Attention: General Counsel  
Email:

- (b) Either Party may change its address for communications by a notice in writing to the other Party in accordance with this Section.

8.5 Language; Governing Law. This Agreement is entered into and will be governed and construed in accordance with the English language. This Agreement is made in accordance with and shall be governed and construed under the laws of New York, New York, USA, without regard to its choice of law principles.

8.6 Dispute Resolution.

- (a) The Parties agree that in the event of a dispute they shall first attempt in good faith to resolve such dispute.
- (b) In the event that such dispute is not resolved on an informal basis, either Party may refer the dispute to the Executive Director of MPP, and to the Senior Vice President, Business Development of Pfizer or equivalent or their respective designees (together, the “**Designated Officers**”).
- (c) In the event that such dispute is not resolved by the Designated Officers within thirty (30) days after submission to such Designated Officers, each Party shall have the right to submit such dispute (except for any intellectual property matter disputes) to non-binding mediation in accordance with the WIPO Mediation Rules.
- (d) In the event that the dispute is not resolved within thirty (30) days following submission to such non-binding mediation, each Party shall have the right to submit such dispute (except for any intellectual property disputes) to final and binding arbitration. The arbitration shall be conducted by three (3) arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce (“**ICC**”). The claimant shall nominate an arbitrator in its request for arbitration. The respondent shall nominate an arbitrator within thirty (30) days of the receipt of the request for arbitration. The two (2) arbitrators nominated by the Parties shall nominate a third arbitrator, in consultation with the

*Execution Version*

Parties, within thirty (30) days after the confirmation of the later-nominated arbitrator. The third arbitrator shall act as chair of the tribunal. If any of the three (3) arbitrators are not nominated within the time prescribed above, then the ICC shall appoint the arbitrator(s). The seat of the arbitration shall be New York, New York, USA, and it shall be conducted in the English language. The Parties undertake to maintain confidentiality as to all aspects of the arbitration, including its existence, content and result, and as to all submissions, correspondence and evidence relating to the arbitration proceedings. The foregoing sentence shall survive the termination of the arbitral proceedings. Notwithstanding the foregoing, a Party may disclose information relating to the arbitration proceedings to the extent that disclosure is required to: (a) protect or pursue a legal right related to the arbitration; (b) enforce or challenge an award in bona fide legal proceedings; (c) respond to a bona fide compulsory order or request for information of a Governmental Authority or Agency; (d) make a disclosure required by securities laws, rules of a securities exchange, or other similar laws, regulations, or rules; or (e) seek legal, accounting, or other professional services. The costs of the arbitration, including, without limitation, the Parties' reasonable legal fees, shall be borne by the unsuccessful Party. However, the arbitral tribunal may apportion such costs between the Parties if it determines that apportionment is reasonable, taking into account the circumstances of the case. The arbitration award shall be final and binding on the Parties, and the Parties undertake to carry out any award without delay. Judgment upon the award may be entered by any court having jurisdiction of the award or having jurisdiction over the relevant Party or its assets.

- (e) The foregoing, however, shall not prevent a Party from seeking and obtaining injunctive relief at any time if in its judgment such action is necessary to avoid irreparable harm. The Parties expressly and irrevocably submit to the jurisdiction of the court of New York, New York, USA for any such injunctive relief.
- (f) Without prejudice to the foregoing, nothing in this Agreement shall prevent or restrict Pfizer or its Affiliates from electing to bring proceedings in relation to patent infringement or from applying for injunctive relief in any country outside United States, to which election MPP hereby agrees.
- (g) The requirement to attempt to resolve a dispute in accordance with this Section 8.6 does not affect a Party's right to terminate this Agreement as provided in Section 6, and neither Party shall be required to follow these procedures prior to terminating this Agreement.

8.7 Assignment. Neither Party may assign its rights and obligations under this Agreement without the other Party's prior written consent, except that Pfizer may, without the consent of MPP, assign its rights and obligations under this

Agreement to one or more of its Affiliates or any successor in interest or acquirer, in whole or in part, of the Patents, Licensed Know-How, Compound, Product and/or Licensed Product. MPP is not entitled to transfer or assign this Agreement or the rights and obligations under this Agreement, by operation of law or otherwise, without the prior written consent of Pfizer. Any attempted assignment or delegation in violation of this Section 8.7 shall be null and void. Subject to the foregoing, this Agreement will inure to the benefit of, and be binding on, the Parties' successors and assigns.

- 8.8 Amendments and Waivers. No amendment or modification hereof shall be valid or binding upon the Parties unless made in writing and signed by both Parties. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No waiver by any Party in one or more instances of any of the provisions of this Agreement or the breach thereof shall establish a precedent for any other instance with respect to the same or any other provision. Furthermore, in case of waiver of a particular provision, all other provisions of this Agreement shall continue in full force and effect.
- 8.9 Force Majeure. Neither Party shall be liable for failure of or delay in performing any obligation under this Agreement, if such failure or delay is due to "Acts of God", weather, fire, or explosion; war, invasion, riot, or other civil unrest; governmental laws, orders, restrictions, actions, embargoes, or blockades; national or regional emergency; injunctions, strikes, lockouts, labor troubles, or other industrial disturbances; failures of any facility for transportation, or any other cause beyond the control of the affected Party ("**Force Majeure**"); provided, however, that the Party affected shall promptly notify the other Party of the force majeure event and shall exert its best efforts to eliminate, cure, or overcome any such causes and to resume performance of its obligations with all possible speed. If an event of Force Majeure occurs, the obligations of the Parties under this Agreement will be suspended during, but no longer than, the continuance of the event of Force Majeure. If the event of Force Majeure continues for two hundred seventy (270) days or more, then the performing Party may terminate this Agreement immediately upon written notice to the non-performing Party.
- 8.10 Entire Agreement. This Agreement, together with its Exhibits, contains the entire agreement between the Parties in respect of the subject matter hereof, and supersedes and cancels all previous agreements, negotiations, commitments, and writings in respect of the subject matter hereof, except that any previous confidentiality agreements shall remain in full force and effect.
- 8.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.

***Execution Version***

- 8.12 Privacy Laws. Pfizer and MPP shall comply with all Applicable Law relating to data privacy, personal data, trans-border data flow, and data protection involved in handling any personal data and information related to each other and their representatives. It shall be the duty of the Pfizer and MPP to ensure that no personally identifiable information that permits the identity of an individual to whom the information applies to be reasonably inferred by either direct or indirect means is shared with each other under any circumstances. This obligation shall survive the expiry of this Agreement.
- 8.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument. Signature pages of this Agreement may be exchanged by facsimile, pdf or through DocuSign, and that any such e-signature shall be given the same legal force and effect as the physical delivery of this Agreement, bearing original handwritten signatures without affecting the validity thereof.

*[signatures appear on following page]*

***Execution Version***

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

*Pfizer:*

**PF PRISM HOLDINGS B.V.**

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Eduard Slijkoord  
Title: Managing Director


*MPP:*

**MEDICINES PATENT POOL FOUNDATION**

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Charles Gore  
Title: Executive Director

**Exhibit A**

**Compound**





**Exhibit B****Patents**

Country	Patent Type	Status	App No.	Filing Date	Title
<a href="#">A.R.I.P.O.</a>	Compound	Filed	<a href="#">AP/P/2021/013602</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Algeria</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Argentina</a>	Compound	Filed	<a href="#">P210102205</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Aruba</a>	Compound	Filed	<a href="#">Awaiting</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Australia</a>	Compound	Filed	<a href="#">2021266232</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bahamas</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">Bahrain</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bangladesh</a>	Compound	Filed	<a href="#">248/2021</a>	08-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Barbados</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bolivia</a>	Compound	Filed	<a href="#">SP-000165-2021</a>	09-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Brazil</a>	Compound	Filed	<a href="#">BR112021022419-0</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Canada</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Chile</a>	Compound	Filed	<a href="#">202102965</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">China P.R.</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Colombia</a>	Compound	Filed	<a href="#">NC2021/0015067</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Costa Rica</a>	Compound	Filed	<a href="#">2021-0558</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Cuba</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Dominican Republic</a>	Compound	Filed	<a href="#">P2021-0232</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Ecuador</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Egypt</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">El Salvador</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Eurasian Patent Convention</a>	Compound	Filed	<a href="#">202192798</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">European Patent Convention</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Georgia</a>	Compound	Filed	<a href="#">15794/1</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Guatemala</a>	Compound	Filed	<a href="#">A-2021-00229</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Honduras</a>	Compound	Filed	<a href="#">HN/P/2021/002695</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Hong Kong</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">India</a>	Compound	Filed	<a href="#">202117051620</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Indonesia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Israel</a>	Compound	Filed	<a href="#">287880</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Japan</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Korea South</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Kosovo</a>	Compound	Filed	<a href="#">KS/P/2021/12</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Kuwait</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Lebanon</a>	Compound	Filed	<a href="#">12283</a>	26-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Macao</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">Malaysia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Mexico</a>	Compound	Filed	<a href="#">MX/a/2021/013679</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Mongolia</a>	Compound	Filed	<a href="#">10-2021-0006800</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">New Zealand</a>	Compound	Filed	<a href="#">782196</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Nicaragua</a>	Compound	Filed	<a href="#">2021-000104-I</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Nigeria</a>	Compound	Filed	<a href="#">280526413368</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">O.A.P.I.</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Oman</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Pakistan</a>	Compound	Filed	<a href="#">Awaiting</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Panama</a>	Compound	Filed	<a href="#">93684-01</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Paraguay</a>	Compound	Filed	<a href="#">65555/2021</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Patent Cooperation Treaty</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Peru</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Philippines</a>	Compound	Filed	<a href="#">1-2021-552851</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Qatar</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Russian Federation</a>	Compound	Filed	<a href="#">2021132570</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Saudi Arabia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Singapore</a>	Compound	Filed	<a href="#">11202112508R</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">South Africa</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Sri Lanka</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Taiwan</a>	Compound	Filed	<a href="#">110129119</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds

Country	Patent Type	Status	App No.	Filing Date	Title
<a href="#">Thailand</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Trinidad &amp; Tobago</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Ukraine</a>	Compound	Filed	<a href="#">a 2021 06382</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United Arab Emirates</a>	Compound	Filed	<a href="#">P6002051/2021</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Filed	<a href="#">17/395139</a>	05-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/170158</a>	02-Apr-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/073982</a>	03-Sep-2020	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/194241</a>	28-May-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/143435</a>	29-Jan-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Uruguay</a>	Compound	Filed	<a href="#">39372</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Uzbekistan</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Venezuela</a>	Compound	Filed	<a href="#">Awaiting</a>	19-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Vietnam</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds

All of the Patents are owned by Pfizer Inc. as of the Effective Date.

**Exhibit C****Territory**

LIC : Low-Income Country  
 LMIC : Lower Middle-Income Country  
 UMIC : Upper Middle-Income Country

Country	Classification
Afghanistan	LIC
Algeria	LMIC
Angola	LMIC
Armenia	UMIC
Bangladesh	LMIC
Belize	UMIC
Benin	LMIC
Bhutan	LMIC
Bolivia	LMIC
Botswana	UMIC
Burkina Faso	LIC
Burundi	LIC
Cabo Verde	LMIC
Cambodia	LMIC
Cameroon	LMIC
Central African Republic	LIC
Chad	LIC
Comoros	LMIC
Congo, Dem. Rep.	LIC
Congo, Rep.	LMIC
Côte d'Ivoire	LMIC
Djibouti	LMIC
Egypt, Arab Rep.	LMIC
El Salvador	LMIC
Equatorial Guinea	UMIC
Eritrea	LIC
Eswatini	LMIC
Ethiopia	LIC
Gabon	UMIC
Gambia, The	LIC
Georgia	UMIC
Ghana	LMIC

Country	Classification
Guatemala	UMIC
Guinea	LIC
Guinea-Bissau	LIC
Haiti	LIC
Honduras	LMIC
India	LMIC
Indonesia	UMIC
Iran	UMIC
Jordan	UMIC
Kenya	LMIC
Kiribati	LMIC
Korea, Dem. People's Rep.	LIC
Kosovo	UMIC
Kyrgyz Republic	LMIC
Lao PDR	LMIC
Lesotho	LMIC
Liberia	LIC
Madagascar	LIC
Malawi	LIC
Mali	LIC
Mauritania	LMIC
Micronesia, Fed. Sts.	LMIC
Moldova	LMIC
Mongolia	LMIC
Morocco	LMIC
Mozambique	LIC
Myanmar	LMIC
Namibia	UMIC
Nepal	LMIC
Nicaragua	LMIC
Niger	LIC
Nigeria	LMIC
Pakistan	LMIC
Papua New Guinea	LMIC
Philippines	LMIC
Rwanda	LIC
Samoa	UMIC
São Tomé & Príncipe	LMIC
Senegal	LMIC
Sierra Leone	LIC

Country	Classification
Solomon Islands	LMIC
Somalia	LIC
South Africa (Public Market)	UMIC
South Sudan	LIC
Sri Lanka	LMIC
Sudan	LIC
Syrian Arab Republic	LIC
Tajikistan	LIC
Tanzania	LMIC
Timor-Leste	LMIC
Togo	LIC
Tonga	UMIC
Tunisia	LMIC
Uganda	LIC
Ukraine	LMIC
Uzbekistan	LMIC
Vanuatu	LMIC
Venezuela	UMIC
Vietnam	LMIC
West Bank and Gaza	LMIC
Yemen, Rep.	LIC
Zambia	LMIC
Zimbabwe	LMIC

## Exhibit D

### Form of Sublicense Agreement

#### *LICENSE AGREEMENT*

This LICENSE AGREEMENT (this “**Agreement**”) is made as of \_\_\_\_\_ (the “**Effective Date**”) by and among the **Medicines Patent Pool**, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembe 7, Geneva 1202, Switzerland (“**MPP**”), and \_\_\_\_\_ a company registered under the laws of \_\_\_\_\_, and having as principal place of business at \_\_\_\_\_ (“**Licensee**”). Each of MPP and Licensee is referred to in this Agreement individually as a “**Party**” and collectively as the “**Parties**”.

#### **RECITALS**

WHEREAS, in accordance with Pfizer-MPP Agreement (as hereinafter defined), MPP has been granted by PF PRISM Holdings B.V., a private limited company (besloten vennootschap) having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“**Pfizer**”), the right to sublicense certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined) regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product, in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);

WHEREAS, MPP is a non-profit organization with a mission to improve the health of people living in the developing world by increasing access to quality, safe, efficacious, and affordable medicines by facilitating access to intellectual property on these medicines;

WHEREAS, Licensee desires to obtain a license from MPP to use the Patents and Licensed Know-How, and MPP is willing to grant to Licensee such a license, each in accordance with the terms and subject to the conditions of this Agreement; and

WHEREAS, the intent of this Agreement is to provide a license to Patents and Licensed Know-How solely as set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

### **1. DEFINITIONS**

- 1.1 “**Affiliate**” shall mean in relation to a Party or Pfizer, any corporation, firm, partnership or other entity that controls, is controlled by or is under common control with that Party or Pfizer (as applicable), but only for so long as such control continues. For the purposes of this definition, “control” (including with

the correlative meanings “controlled by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interests (whether directly or pursuant to any option, warrant, or other similar agreement) of such entity.

- 1.2 **“Agency”** shall mean, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of a regulatory approval or, to the extent required in such country, price approval, for a pharmaceutical product in such country.
- 1.3 **“Agreement Quarter”** shall mean any period of three months ending on the last day of February or May or August or November.
- 1.4 **“Applicable Law”** shall mean any and all laws, statutes, ordinances, regulations, permits, orders, decrees, judgments, directives, rulings or rules of any kind whatsoever that are promulgated by a federal, state, provincial, municipal, or Agency, in each case pertaining to any of the activities contemplated by this Agreement, including any regulations promulgated thereunder, all as amended from time to time.
- 1.5 **“Business Day”** shall mean a day (other than a Saturday or Sunday) on which the banks are open for normal business in New York, USA.
- 1.6 **“Calendar Quarter”** shall mean any period of three (3) months ending on the last day of March or June or September or December.
- 1.7 **“cGMP”** shall mean all applicable standard relating to current good manufacturing practices for fine chemical, intermediates, bulk products and/or finished pharmaceutical drugs, including (a) all applicable requirements detailed in the FDA’s current Good Manufacturing Practices regulations, 21 C.F.R. Pars 210 and 211, (b) all applicable requirements detailed in the EMA’s “EU guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use,” and (c) all applicable laws promulgated by any Agency having jurisdiction over the manufacture of the applicable compound or pharmaceutical drug product, as applicable.
- 1.8 **“Commercialization”** or **“Commercialize”** shall mean sale, import, or export of the Licensed Product by Licensee to an unrelated entity solely for the purposes of making the Licensed Product available in the Territory for use in the Field.
- 1.9 **“Compound”** shall mean (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-Cyano-2-[(3*S*)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-*N*-(trifluoroacetyl)-L-valyl]-3-

azabicyclo[3.1.0]hexane-2-carboxamide, which has the molecular formula  $C_{23}H_{32}F_3N_5O_4$  and having the structure to be set forth on **Appendix 1** attached hereto, as referred to internally by Pfizer as PF-07321332. For clarity, “Compound” includes all forms of (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-Cyano-2-[(3*S*)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-*N*-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, including but not limited to, isomers, stereoisomers, diastereomers, tautomers, hydrates, solvates, crystal forms including crystalline forms and co-crystalline forms, amorphous forms, polymorphs, metabolites and prodrugs thereof. Additionally, “Compound” includes all deuterated forms.

- 1.10 “**Control**” or “**Controlled**” shall mean, with respect to intellectual property rights, that Pfizer, a Party or one of their respective Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide or grant a license or sublicense to such intellectual property rights as provided for in this Agreement without violating the terms of any other agreement or other arrangement with or requiring any payment to any Third Party
- 1.11 “**Customer**” shall mean the Third Party who is buying the Licensed Product from Licensee, but shall not include Pfizer, its Affiliates, or an MPP Licensee.
- 1.12 “**Field**” shall mean the treatment and/or prevention of COVID-19 caused by SARS-CoV-2.
- 1.13 “**Government**” or “**Governmental Authority**” is to be broadly interpreted and includes: (a) any national, federal, state, local, regional, or foreign government, or level, branch, or subdivision thereof; (b) any multinational or public international organization or authority; (c) any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power; (d) any court, tribunal, or governmental arbitrator or arbitral body; (e) any government-owned or -controlled institution or entity; (f) any enterprise or instrumentality performing a governmental function; and (g) any political party.
- 1.14 “**Government Official**” is to be broadly interpreted and includes: (a) any elected or appointed Government official (e.g., a legislator or a member of a ministry of health); (b) any employee or person acting for or on behalf of a Government, a Government department or agency, an institution or entity owned or controlled by a Government (e.g., a healthcare professional employed by a Government-owned or -controlled hospital, or a person serving on a healthcare committee that advises a Government), or an enterprise or instrumentality performing a governmental function; (c) any candidate for public office, or officer, employee, or person acting for or on behalf of a political party or candidate for public office; (d) an employee or person acting for or on behalf of a public international organization (e.g., the United Nations, the Red Cross, or the World Bank); (e) any member of a military or a royal or ruling family; and (f) any person otherwise categorized as a Government official under Applicable Law.



- 1.15 **“Improvements”** shall mean any (patentable or unpatentable) new or improved use, formulation, process, improvement, invention, development or finding related to the Compound, Product and/or the Licensed Product, or any (patentable or unpatentable) other pharmaceutical product containing or otherwise using Compound, or any further invention (patentable or unpatentable) that relates to the development, manufacture, formulation or use of the Licensed Products, Products and/or Compound or incorporate or are based on the Patents or Licensed Know-How, Controlled by Licensee or any of its Affiliates as of the Effective Date or during the term of the Sublicense. For the avoidance of doubt, “Improvements” shall include any patent rights, Know-How or other intellectual property rights related to the Compound, Product and/or Licensed Product or that are necessary or useful for the development, manufacture and/or commercialization of Pfizer’s pharmaceutical product(s) containing or otherwise using the Compound, in each case that are Controlled by Licensee or its Affiliates as of the Effective Date or at any time during the term of this Agreement.
- 1.16 **“Key Approval”** shall mean any technical, medical, scientific or other license, registration, authorization or approval of any Agency (including any approval of a New Drug Application or Biologic License Application) necessary for the development, manufacture or commercialization of a pharmaceutical product in any regulatory jurisdiction.
- 1.17 **“Know-How”** shall mean any and all confidential or proprietary information and materials, including discoveries, improvements, processes, methods, protocols, formulas, molecular constructs, reagents, assays, data, results, inventions, trade secrets, compositions of matter (including compounds), formulations, and findings, in each case, patentable or otherwise, and including any copyrights therein.
- 1.18 **“Licensed Know-How”** shall mean all Know-How that (a) is Controlled by Pfizer or any of its Affiliates as of the effective date of the Pfizer-MPP Agreement, (b) directly relates to the use of the Compound, Product or Licensed Product in the Field, and (c) is not in the public domain or otherwise generally known. For the avoidance of doubt, (i) Licensed Know-How shall not include any Know-How to the extent solely and directly related to any other Pfizer compound or to the extent related to the use of the Compound, Product or Licensed Product outside the Field and (ii) Licensed Know-How includes only that Know-How, designated by Pfizer in its sole discretion, necessary for the manufacture, registration and commercialization of the Compound and/or Licensed Product for use in the Field. For the avoidance of doubt, Licensed Know-How excludes any Know-How related to ritonavir that has been (either as of the Effective Date or at any time during the term of this Agreement) in-licensed by Pfizer from any Third Party.
- 1.19 **“Licensed Product”** shall mean a Product co-packaged and co-administered with the pharmaceutical product ritonavir, (a) where each dose to be administered to a patient consists of (i) Product containing three hundred (300) mg of Compound

and (i) one hundred (100) mg of ritonavir and (b) that is labeled for the administration of two (2) doses per day for the course of treatment.

For purposes of calculating Net Sales, when Licensed Product is sold for Stockpiling purposes in a form other than final form, Licensed Product will refer to Licensed Product in final or bulk form. “Stockpiling” shall mean activities conducted by a Governmental Authority or Public Purchasers to address public health emergencies by purchasing and maintaining inventories of Licensed Product for distribution and use in responding to such emergencies. Stockpiling may apply to purchases of finished or bulk form pharmaceutical Licensed Products or bulk forms of Product or Compound used to make such Licensed Products.

For the avoidance of doubt, any sale of Licensed Products in bulk form or for a Clinical Trial may only take place if permitted and approved in advanced in writing by Pfizer.

- 1.20 “**MPP Licensee(s)**” shall mean any Third Party to whom MPP has granted a sublicense of the rights granted to MPP by Pfizer under and pursuant to the terms of the Pfizer-MPP Agreement.
- 1.21 “**Net Sales**” shall mean the gross amounts invoiced by Licensee or its Affiliate for sales of Licensed Products to Customers, less the sum of the following actual and customary deductions:
- (a) cash, trade, quantity and other discounts, including chargebacks, retroactive price reductions, rebates (whether or not Government-mandated), and discounts in the form of wholesaler inventory management fees;
  - (b) sales, value added (only to the extent of amounts actually paid and not refunded, reimbursed or credited), use, tariff, import/export duties or other excise taxes when included in the gross invoice price, but not value-added taxes assessed upon such sales that are not included in the gross invoice price or income taxes on income derived from such sales;
  - (c) transportation and associated insurance, freight, packaging and customs charges when included in the gross invoice price;
  - (d) allowances or credits to customers because of rejections, returns, or recalls; and
  - (e) deductions for bad debts, not to exceed two percent (2%) of the total amount invoiced, in accordance with International Financial Reporting Standards principles, provided that such amounts will be included in Net Sales when recovered.

For purposes of calculating Net Sales, a sale to an Affiliate for end use by the Affiliate will be treated as a sale at list price. End use does not include: (a) use in a Clinical Trial if for no cost or for *de minimis* value, (b) charitable or compassionate use purposes if for no cost or for *de minimis* value, or (c) quantities provided for resale where royalties will be paid to Pfizer on the resale. For the avoidance of doubt, Net Sales shall not include (i) consideration paid or owed to Licensee for any sale to Pfizer, an Affiliate of Pfizer, or an MPP Licensee that is not for end use by each of such parties, or (ii) consideration paid or owed to Pfizer or its Affiliates for any use or sale by Pfizer or its Affiliates of Licensed Product sold to Pfizer or its Affiliates by Licensee. Net Sales and all deductions allowed in computing Net Sales shall be determined on an accrual basis in accordance with International Financing Reporting Standards principles, consistently applied.

- 1.22 **“Non-Territory Patents”** shall mean any Patents, granted or pending, in any country that is not included in the Territory (as hereinafter defined). For the avoidance of doubt, to the extent international and regional patent applications are included in Patents, such international and regional patent applications are Non-Territory Patents only with respect to countries that are not included in the Territory.
- 1.23 **“Own Use”** shall mean the act of Commercialization and/or the act of registration of the Licensed Product in the Territory for use in the Field.
- 1.24 **“Patents”** shall mean any unexpired letters patent or any pending patent applications as set forth in **Appendix 2** attached hereto, that are granted or pending, relating to the Compound and/or Licensed Product, including divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, pediatric exclusivity, and the like of any such patents and patent applications, and international (e.g., WIPO), regional (e.g., EP or EA), and foreign national equivalents of the foregoing, in each case to the extent Controlled by Pfizer or any of its Affiliates.
- 1.25 **“Pfizer Field”** shall mean the treatment and/or prevention of diseases caused by coronaviruses.
- 1.26 **“Pfizer-MPP Agreement”** shall mean the license agreement entered into between Pfizer and MPP on November 15, 2021.
- 1.27 **“Pfizer Trademarks”** shall mean trademarks, service marks, logos, Internet domain names, trade dress, trade names, and corporate names, now existing or hereafter adopted or acquired, whether registered or unregistered, including without limitation any applications or registrations therefor, and all goodwill connected with the use thereof and symbolized thereby, that are owned, controlled or used by Pfizer or its Affiliates.

- 1.28 **“Product”** shall mean any pharmaceutical or biological composition or preparation (in any and all dosage forms, formulations and delivery modes) containing the Compound as its sole active ingredient, including any Improvements to the foregoing, (a) for sale or use by prescription, over-the-counter or any other method, or (b) for administration to, or use with, human patients in a human clinical trial (**“Clinical Trial”**) to the extent permitted pursuant to Section 3.3 of this Agreement. For clarity, Product shall not include any pharmaceutical or biological composition or preparation containing both the Compound and another active ingredient in a single formulation.
- 1.29 **“Public Market”** shall mean, with respect to a country in the Territory, sales to the Government and Public Purchasers.
- 1.30 **“Public Purchasers”** shall mean with respect to a country in the Territory (a) the following organizations to the extent that they are not for profit organizations and operate in such countries: (i) Non-Governmental Organizations to the extent that they are recognized by the applicable local government ministries from such country; (ii) UN-related organizations working for or in such country, including but not limited to UNDP and UNICEF; (iii) Not-for-profit organizations including without limitation, Médecins Sans Frontières, Save-the-Children, OXFAM and the International Committee of the Red Cross (ICRC) to the extent that they are recognized by the applicable local government ministries from such countries; (iv) programs funded by funding mechanisms, including without limitation, UNITAID, PEPFAR, USAID, and Global Fund; and agencies based outside the Territory to the extent that they are supporting implementation of the organizations described in clauses (i) through (iii) above locally in such country, and (b) nominally for profit procurement organizations but only to the extent that such procurements are supporting not-for-profit programs in such country as described in (a) of this definition within the Territory.
- 1.31 **“Retail”** shall mean sale, import, or export of the Licensed Product by Licensee to another MPP Licensee for the purpose of making the Licensed Product available in the Territory for the other MPP Licensee’s Own Use.
- 1.32 **“Stringent Regulatory Authority”** or **“SRA”** shall mean an Agency which is: (a) a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before 23 October 2015); or (b) an ICH observer, being the European Free Trade Association, as represented by Swissmedic, and Health Canada (as before 23 October 2015); or (c) an Agency associated with an ICH member through a legally-binding, mutual recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 October 2015).
- 1.33 **“Territory”** shall mean those countries set forth in **Appendix 3** attached hereto.

- 1.34 **“Territory Patents”** shall mean any Patents, granted or pending, in any country within the Territory. For the avoidance of doubt, to the extent international and regional patent applications are included in Patents, such international and regional patent applications are Territory Patents only with respect to countries within the Territory.
- 1.35 **“Third Party(ies)”** shall mean any party other than MPP, Licensee, Pfizer and their respective Affiliates.
- 1.36 **“Valid Claim”** shall mean a claim of any issued and unexpired patent or pending patent application whose validity, enforceability, or patentability has not been affected by any of the following: (a) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or (b) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, Governmental Authority, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or unappealed within the time allowed for appeal.
- 1.37 **“Vend”** shall mean sale, import, or export of the Compound or Product by Licensee to another MPP Licensee for the purpose of manufacturing the Licensed Product for such other MPP Licensee’s Own Use.
- 1.34 **Other Terms.** The definition of each of the following terms is set forth in the Section of this Agreement indicated below:

Defined Term	Section
Agreement	Preamble
BIS	8.4
Breach	8.5(g)
breaching party	12.2
Claims	9.3
Clinical Trial	1.28
Combination	2.3
Confidential Information	13.1
Designated Officers	14.7(b)
Disclosure Right	4.7
EAR	8.4
Effective Date	Preamble
EUA	3.8
FCPA	8.5(c)
ICC	14.7(d)
Improvement License	6.1
Indemnitees	9.3
LIC Territory	7.1
Licensee	Preamble
Losses	9.3

MPP	Preamble
non-breaching party	12.2
OFAC	8.4
Officials	8.5(b)
Option and ROFR	6.2
Out-of-Field License	6.2
Party or Parties	Preamble
Payments	8.5(b)
Person	8.4
Pfizer	Recitals
Pfizer Consent Right	14.3
Royalty Term	7.4
Sanctions	8.4
Sanctions Targets	8.4
Trade Control Laws	8.4
WHO	2.1(a)

## 2. SCOPE OF LICENSE GRANT

2.1 License Grant within the Territory. Subject to the terms and conditions of this Agreement, MPP hereby grants to Licensee a non-exclusive, non-transferable, non-sublicensable, royalty-bearing right license under the Territory Patents and Licensed Know-How to:

- (a) manufacture the Compound, Product and Licensed Product at a facility that is in the Territory (excluding involvement of any Sanctions Targets except as expressly permitted pursuant to Section 8.4 of this Agreement) and that is approved by an SRA or pre-qualified by the World Health Organization (“WHO”);
- (b) Commercialize the Licensed Product by itself or through its Affiliates in the Field in the Territory (excluding involvement of any Sanctions Targets except as expressly permitted pursuant to Section 8.4 of this Agreement);
- (c) Retail the Licensed Product to other MPP Licensees for such other MPP Licensees’ Own Use in the Territory;
- (d) register the Licensed Product in the Field in the Territory by itself or, subject to Section 2.7 of this Agreement, through its Affiliates for use in the Field for Section 2.1(b) and or Section 2.1(e) of this Agreement;
- (e) sell the Licensed Product to Public Purchasers in the Territory for the sole purpose of enabling the Public Purchasers to supply the Licensed Product solely in the Territory for use in the Field; and
- (f) Vend the Compound and Product.

- 2.2 License Grant Outside the Territory. Subject to the terms and conditions of this Agreement, MPP hereby grants to Licensee a non-exclusive, non-transferable, non-sublicensable, royalty-bearing right and license under the Non-Territory Patents and Licensed Know-How to:
- (a) manufacture the Compound, Product and Licensed Product at a facility that is in a non-Territory country (excluding involvement of any Sanctions Targets except as expressly permitted pursuant to Section 8.4 of this Agreement) and that is approved by an SRA or pre-qualified by the WHO;
  - (b) export Licensed Product manufactured by Licensee (pursuant to the rights granted under Section 2.2(a) of this Agreement) outside the Territory to the Territory for its Own Use;
  - (c) Retail Licensed Product manufactured (pursuant to the rights granted under Section 2.2(a) of this Agreement) outside the Territory in the Territory to other MPP Licensees for such other MPP Licensees' Own Use; and
  - (d) sell Licensed Product to Public Purchasers outside the Territory for the sole purpose of enabling such Public Purchasers to supply Licensed Product in the Territory for use in the Field; and
  - (e) to Vend the Compound and Product.
- 2.3 License Restrictions. No rights are granted under this Agreement for any other purpose. No license or right is granted by implication or otherwise with respect to the Compound, Product and/or Licensed Product, except as expressly granted herein. Subject to the above and except as expressly permitted in this Agreement, Licensee shall not be entitled, directly or indirectly, to manufacture, use, Commercialize, Retail, Vend, register with Agencies, distribute, offer for sale, sell and/or donate the Compound, Product and/or the Licensed Product for any other purpose or in combination with any other substance, product, Licensed Product, intermediate, and/or active pharmaceutical ingredient (whether co-packaged (other than, with respect to Product, co-packaged with ritonavir in the form of Licensed Product), co-formulated or otherwise) ("**Combination**") without the prior written approval of Pfizer in its sole discretion, in which event any such approval shall be subject to separate terms and conditions to be negotiated.
- 2.4 No Waiver. For the avoidance of doubt, nothing in this Agreement shall be construed to prevent Licensee from engaging in activities inside or outside the Territory where such activities would not (a) infringe the Patents and/or any other intellectual property rights of Pfizer; (b) use or misappropriate Licensed Know-How; and/or (c) use or require the use of any of Pfizer's confidential information. Licensee acknowledges that Pfizer has expressly reserved all its rights under the Patents, except as expressly set forth in the Pfizer-MPP Agreement and this Agreement, and under any additional patents and/or patent applications

Controlled (either as of the Effective Date or at any time during the term of this Agreement) by Pfizer or its Affiliates. For the avoidance of doubt, it shall not be deemed a breach by Licensee to supply Compound, Product or Licensed Product outside the Territory into a country where the Government of such country has, to the extent permitted by applicable law, granted or required to be granted to Licensee a compulsory license under the Patents relating to such Compound, Product or Licensed Product allowing for the importation of such Compound, Product or Licensed Product into such country, provided that (a) Licensee's supply of Compound, Product or Licensed Product into such country is solely within the scope and geographic range of such compulsory license and only for the duration that such compulsory license is in effect and (b) Licensee does not use or misappropriate Licensed Know-How and/or misappropriate, use or require the use of any of Pfizer's Confidential Information. Licensee also acknowledges that Pfizer does not waive any applicable statutory and/or regulatory exclusivities owned or controlled by Pfizer, except as expressly set forth in the Pfizer-MPP Agreement. Nothing in this Agreement shall provide a right to Vend, Retail, donate, offer for sale, sell or otherwise distribute the Compound, Product or Licensed Product outside the Territory for further offer for sale, sale, donation or distribution of the Compound, Product or Licensed Product outside or for use outside the Territory.

- 2.5 Retained Rights. Licensee acknowledges that the licenses granted pursuant to Sections 2.1 and 2.2 of this Agreement are non-exclusive and that (a) MPP retains the right to grant licenses to other MPP Licensees, and (b) Pfizer retains the right in its sole discretion to (i) grant additional licenses or distribution rights for the Compound, Product and/or Licensed Product to Third Parties and (ii) make, use, import, offer for sale, sell and/or donate the Compound, Product and/or Licensed Product (or any other pharmaceutical product containing the Compound or Product) on its own behalf.
- 2.6 Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is "not for resale" outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP



or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

- 2.7 Affiliate Performance. If Licensee wishes to Commercialize the Licensed Product through an Affiliate of Licensee acting on Licensee's behalf, Licensee shall first provide prior written notification to MPP and Pfizer. Upon MPP's or Pfizer's request, Licensee will provide MPP or Pfizer with a written copy of Licensee's agreement(s) with such Affiliate and will certify to MPP and Pfizer in writing that such agreement(s) is/are consistent with the terms and conditions of this Agreement. MPP and Pfizer have the right to review all such agreements to verify consistency with the terms and conditions of this Agreement. In the event that any inconsistency is found which had not been specifically discussed with, and agreed to in writing by, Pfizer, MPP or Pfizer shall have the right to require Licensee to amend such agreement with such Affiliate to be consistent with the terms and conditions of this Agreement. Notwithstanding any such review by MPP and Pfizer, Licensee shall remain responsible for ensuring that the terms and conditions of any such agreement(s) with such Affiliate is/are consistent with the terms and conditions of this Agreement, and Licensee shall be responsible for any liability arising from any inconsistency. Licensee shall be held responsible for the actions of any of its Affiliates or any other permitted assignees/transferees in connection with this Agreement, and all obligations of Licensee under this Agreement in connection with the sale and Commercialization of the Licensed Product in the Territory will be deemed to apply to such activities conducted by any of its Affiliates and permitted assignees/transferees. Any rights to manufacture or Commercialize Compound, Product or Licensed Product granted by Licensee to an Affiliate of Licensee shall automatically be terminated in the event that such Affiliate ceases to be an Affiliate of Licensee.
- 2.8 No Other Licenses. The licenses granted under Sections 2.1 and 2.2 of this Agreement do not include a license to other intellectual property rights that Pfizer may possess with respect to the Compound, Product and/or the Licensed Product, other than the Patents and Licensed Know-How, as expressly provided herein. For clarity, licenses granted under Sections 2.1 and 2.2 of this Agreement do not include a license to processes or procedures for the manufacture, production, packaging, labeling, warehousing, and quality control testing of the Compound, Product and/or the Licensed Product that are not expressly included in the Patents and/or Licensed Know-How. Except as expressly set forth in this Agreement, (a) MPP does not grant any license to Licensee under any of Pfizer's intellectual property rights (including, without limitation, patents, patent applications, Know-How or rights to any Pfizer proprietary compounds or drug substances other than the Compound or for use of the Compound, Product or Licensed Product outside the Field or outside the Territory), and (b) Licensee shall not take any action which would constitute an infringement of any of the Patents.

- 2.9 License Purpose. Notwithstanding anything to the contrary herein, Licensee acknowledges that the licenses granted under this Section 2 are granted solely under and with respect to the Patents and Licensed Know-How for the sole purpose of final supply of the Licensed Products in the Territory.

### 3. DEVELOPMENT, MANUFACTURE AND REGISTRATION

- 3.1 Development Generally. As of the Effective Date and subject always to Pfizer's retained rights to the Patents and Licensed Know-How and the limitations and restrictions set forth herein, Licensee shall have full control, responsibility (financial and otherwise) and authority, at Licensee's cost and expense, over development, registration, importation, manufacture, and Commercialization of the Licensed Products to be sold or supplied by Licensee in the Territory under this Agreement.
- 3.2 Data Package. Upon Licensee's written request to MPP and submission of relevant access information requested by MPP, Pfizer shall make available to Licensee, on a confidential basis, a discrete data package related to the Compound, the contents of which shall have been determined by Pfizer in its sole discretion. Prior to receiving access to the data package, Licensee may request in writing from MPP, in which event MPP shall provide to Licensee, a high-level summary of topics included in the data package, provided that such summary shall not create any obligation on the part of Pfizer to include any specific piece of information in the data package. Pfizer shall not be required to provide any other technical support or technical assistance to a Sublicensee for any reason.
- 3.3 Research and Studies. Subject to Pfizer's prior written approval (which may be provided or withheld in Pfizer's sole discretion), Licensee may conduct basic research or pre-clinical, clinical or other studies (including Clinical Trials) with the Compound, Product or Licensed Product. For the avoidance of doubt, Pfizer shall have the right to review the study design, specifications, protocol and related materials of any such proposed studies. In the event that any such studies have been approved by Pfizer, Licensee will pay for any necessary supplies, and Licensee agrees to fully comply with all Applicable Law in connection with such Clinical Trials. Unless specified otherwise in a writing signed by Pfizer, Pfizer will not be the sponsor or hold regulatory responsibility for such Clinical Trials and Licensee, pursuant to Section 9.3(a), shall indemnify Pfizer for any liability arising, directly or indirectly, from or based on the conduct of any Clinical Trial or study. Without limiting the foregoing, in the event Pfizer approves any such studies or trials in accordance with this Section 3.3, then, at the option of Pfizer, Pfizer may, but shall have no obligation to, have its representative review any approved studies, but in no event will such activities relieve the sponsor of such Clinical Trials from their oversight and monitoring obligations.
- 3.4 Research Data Reporting. Upon completion of any such studies described in Section 3.3 of this Agreement, Licensee shall furnish free of charge to Pfizer and its Affiliates in the English language all data and information, especially any

adverse drug experiences, derived from any such studies (including Clinical Trials) carried out by Licensee relating to the Licensed Product, in such detail and at such times as Pfizer may reasonably request for regulatory purposes, use in connection with the exercise of the licenses granted to Pfizer under Sections 6.1 or 6.2, other non-commercial and internal use and disclosure to any Third Party in compliance with the contractual obligations of Pfizer and its Affiliates. Any such Affiliates which are recipients of such information pursuant to the foregoing shall be under the same obligation of confidentiality as set forth in this Section. If Pfizer and its Affiliates want to use the data and information for any other purpose, Licensee and Pfizer shall negotiate in good faith.

- 3.5 Manufacturing Obligations. Licensee agrees that it will manufacture the Compound, Product and Licensed Product in a manner consistent with (a) WHO Prequalification standards; or (b) the standards of any SRA. Licensee will manufacture and sell the Compound, Product and Licensed Products in accordance with all laws and regulations relevant to the manufacture and sale of the Compound, Product and Licensed Product, including cGMP, and in accordance with good industry practice. Licensee will not sell any Licensed Product without WHO Prequalification or SRA approval, or through any provisional or emergency use authorizations available through WHO or an SRA and will comply with applicable regulatory requirements in the country of manufacturing and the country of sale.
- 3.6 Regulatory Generally. Licensee shall be solely responsible for obtaining all regulatory approvals, including any Key Approvals and local regulatory approvals, necessary for Licensee to develop, manufacture, use, Retail, Vend and Commercialize the Compound, Product and Licensed Product as permitted under this Agreement. Pfizer, to the extent necessary, will reasonably cooperate with limited administrative requests (e.g., confirmatory letter of license grant) from Licensee to enable registration of the Licensed Product in the Territory.
- 3.7 Regulatory Approval. Licensee shall submit a complete file for WHO Prequalification or any SRA approval within thirty-six (36) months after the Effective Date for any existing formulation of the Licensed Products, or within a period to be agreed among Pfizer, MPP and Licensee for any new formulation of the Licensed Product. Licensee will diligently pursue such applications following submission. Licensee agrees, where applicable and to the extent that it is able, to not seek and waive regulatory exclusivity in the Territory in relation to any data relating to the Licensed Products. Licensee acknowledges and agrees that it shall be permitted to use any such WHO Prequalification or SRA Approval solely to support any filings to an Agency for Key Approval to Commercialize Licensed Product in the Field in the Territory and shall in no event be permitted to use any such WHO Prequalification or SRA approval as the basis of, or for a reference to, support for any filings to an Agency for Key Approval to Commercialize Licensed Product outside the Field and/or outside the Territory.

- 3.8 Development and Regulatory Reporting. For the period beginning from the Effective Date, within ten (10) Business Days following the end of each Calendar Quarter, Licensee shall provide MPP with a quarterly written report covering all its activities related to the development and testing of all Licensed Products and/or Compound (as permitted and to the extent applicable) and the obtaining of necessary governmental approvals, including, but not limited to (and to the extent applicable and permitted) its (a) Licensed Products, Product, and/or Compound in its development pipeline, (b) status of development of each Licensed Product, Product and/or Compound in development, (c) regulatory filing plan for WHO Prequalification Programme and/or an SRA, and where applicable any local regulatory filings, for each Licensed Product, (d) a list of Agencies, including as applicable the FDA, WHO and authorities in the countries within the Territory for which such Key Approvals or other local approvals or authorizations have been filed and/or obtained for any Licensed Product, (e) summary of work completed and in progress, (f) current schedule of anticipated events and milestones, (g) anticipated market introduction dates, (h) all bioequivalence data generated by or on behalf of Licensee related to Licensed Product, and (i) other activities, if applicable. Licensee will also report to MPP and Pfizer the date of first commercial sale of each Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an emergency use authorization (“EUA”) or Key Approval within five (5) business days thereafter.
- 3.9 Development and Regulatory Meetings. The Parties agree to meet on a quarterly basis or as reasonably requested by the MPP, to review development and filing status and also regarding such reports concerning Licensed Product, Product and/or the Compound. MPP agrees that information contained in quarterly and other such reports shall be treated as Confidential Information of Licensee; provided, however, that such information may be shared with Pfizer (with Pfizer treating such reports as Confidential Information) and that aggregated data may be publicly disclosed by MPP. Licensee shall, at its own expense and using its own resources, and using all due care in accordance with the prevailing standard of professional competence in a regulatory function in the pharmaceutical industry, obtain, maintain and operate in compliance with (a) the Key Approvals and (b) all other authorizations, licenses, permits, registrations, and regulations which may from time to time be required by any Agency for Licensee to import, manufacture, promote, and sell the Licensed Product in the Territory. Licensee will not sell Licensed Product in any country in the Territory prior to obtaining both local health Agency approval or authorization in the country in the Territory where the Licensed Product is sold and Commercialized and relevant approval or authorization for the manufacture of Licensed Product in the country of manufacture. Licensee shall provide quarterly written reports to MPP notifying MPP about the registration process and providing MPP with any other information in this regard that MPP may reasonably require which such reports may be shared with Pfizer (with Pfizer treating such reports as Confidential Information). Licensee shall not transfer, assign, or otherwise convey any of the authorizations, registrations, or permits related to the Licensed Product, as set

forth above in this Section 3, to any Affiliate without the prior written notice to MPP and Pfizer.

- 3.10 Assignment of Regulatory Approvals. Licensee shall not transfer, assign, or otherwise convey any of the authorizations, registrations, or permits related to the Licensed Product, as set forth above in this Section 3, to any Third Party without the prior written permission of both MPP and Pfizer, which permission may be withheld at MPP's or Pfizer's sole discretion.
- 3.11 Commercialization. Licensee shall promote, Commercialize and sell the Licensed Product in strict adherence to regulatory, professional, and legal requirements in the Territory and solely to the extent permitted under, and consistent with, all applicable regulatory approvals (including, without limitation, Key Approvals). In no event shall Licensee, directly or indirectly, promote, market, offer for sale, sell, donate or otherwise distribute the Licensed Product for any use outside of the Field or otherwise perform any off-label promotion, marketing or Commercialization of the Licensed Product. Licensee shall do nothing which would jeopardize the good will or reputation of MPP or Pfizer or the reputation of the Compound, Product and/or Licensed Product.
- 3.12 Pharmacovigilance. Licensee shall maintain until the termination of this Agreement (or, as applicable, until the rights and obligations intended to survive termination of this Agreement have been fulfilled) pharmacovigilance and risk management systems, procedures and documentation needed to perform and comply with its regulatory obligations and its related obligations under this Agreement. Licensee shall ensure that it will comply with all Applicable Law regarding Licensed Product in the Territory, including, without limitation, those laws and regulations relating to risk management, drug safety and pharmacovigilance. If Licensee becomes aware of any adverse reaction relating to Licensed Product in connection with this Agreement, Licensee shall inform MPP and Pfizer within twenty-four (24) hours of its becoming aware and cooperate with Pfizer in fulfilling Pfizer's reporting responsibilities under Applicable Law. Licensee will be responsible for fulfilling all pharmacovigilance activities pursuant to the local regulations and requirements for the Licensed Products in the Territory and provide MPP and Pfizer with a report containing information regarding all such activities. Such report shall be provided annually, on February 1 of each year, and otherwise on reasonable request by MPP or Pfizer to both MPP and Pfizer's pharmacovigilance contact as may be designated by Pfizer from time to time. Licensee shall notify MPP and Pfizer forthwith of the receipt of an enquiry from an Agency in the Territory relating to Licensed Product that concerns any safety issue. If Licensee becomes aware of any action that may be, will be or has been taken by an Agency for a safety reason connected with Licensed Product, it shall immediately, and in any event no later than twenty-four (24) hours after receiving such notice from such Agency, notify MPP and Pfizer in writing (including, but not limited to, email communications) with available details regarding the same.

- 3.13 Recalls and Withdrawals. Unless otherwise required by Applicable Law, Licensee shall not institute a recall or other market withdrawal of Licensed Product without first providing prior written notice to MPP and Pfizer, such notice to set forth the basis of the recall and market withdrawal. In the event that Licensee receives any notice from an Agency requesting or otherwise directing Licensee to initiate a recall or other market withdrawal of Licensed Product, Licensee shall immediately, but in any event within twenty-four (24) hours of its receiving such notice, provide any such notice to MPP and Pfizer. Notwithstanding the obligations set forth herein, Licensee shall be solely responsible and liable for any recall or other market withdrawal of Licensed Product and in no event shall Pfizer or MPP have any liability with respect thereto.
- 3.14 Conflicts. This Section 3 shall always be subject to the provisions of Section 4 of this Agreement. Where there is any inconsistency between this Section 3 and Section 4 of this Agreement, Section 4 of this Agreement shall prevail.

#### **4. SUPPLY OF COMPOUND, PRODUCT OR LICENSED PRODUCT**

- 4.1 Pfizer Supply Right. Licensee hereby agrees to supply reasonable amounts of ritonavir, materials used in the synthesis of the Compound, the Compound, Product and/or Licensed Product, as requested by Pfizer in writing, to Pfizer or its Affiliates at the actual cost of goods (verifiable via Third Party audit) plus a ten percent (10%) markup under a supply agreement containing such other reasonable and customary terms and conditions as are agreed by Pfizer and Licensee in good faith. Such reasonable amounts of supply shall be determined by Pfizer taking into good faith consideration the total number of MPP Licensees and any need for Licensee to use ritonavir for its products for the treatment of HIV and Pfizer's otherwise unmet twelve (12)-month forecasted demand.
- 4.2 Third Party Suppliers. If Licensee wishes to obtain the Compound, Product and/or Licensed Product from a Third Party source, Licensee shall notify Pfizer through MPP of the intended source prior to making any commitments to purchase the Compound, Product and/or Licensed Product. Pfizer will determine at its sole discretion whether and on what terms to grant a license to the intended source to produce the Compound, Product and/or Licensed Product or inform Licensee whether such license already exists.
- 4.3 Supply from MPP Licensees. Subject to Sections 4.2 and 4.4 of this Agreement, Licensee shall have the right to source the Compound, Product and/or Licensed Product from an MPP Licensee. Licensee's Commercialization of any Licensed Product sourced from an MPP Licensee shall be subject to the terms and conditions of this Agreement and be royalty-bearing in accordance with Section 7 of this Agreement.
- 4.4 MPP Licensee Supply Agreements. Licensee shall not enter into any agreements with any other MPP Licensee with respect to Compound, Product and/or Licensed

Product without providing prior notice to Pfizer through MPP. All terms of the agreement between Licensee and an MPP Licensee must be consistent with this Agreement or written approval needs to be obtained by Pfizer. Licensee shall certify to Pfizer through MPP in writing that its arrangement(s) with each MPP Licensee with respect to Compound, Product and/or Licensed Product is consistent with the terms and conditions of this Agreement. Pfizer shall have the right to review all such agreements to verify consistency with the terms and conditions of this Agreement. If any inconsistency is found which had not been specifically discussed and agreed with Pfizer, Pfizer shall have the right to require Licensee to terminate its agreement(s) with such MPP Licensee. Notwithstanding any such review by MPP and Pfizer, Licensee shall remain responsible for ensuring that the terms and conditions of any such agreement(s) with such Affiliate is/are consistent with the terms and conditions of this Agreement, and Licensee shall be responsible for any liability arising from any inconsistency.

- 4.5 MPP Licensee Supply Reporting. Licensee shall not be obliged to disclose to MPP the financial terms of its agreement(s) with an MPP Licensee but shall provide MPP with quarterly reports in accordance with Section 7.5 of this Agreement that shall include the quantities of Compound and/or Licensed Product being supplied to Licensee by each MPP Licensee, which will be shared by MPP with Pfizer.
- 4.6 Conditions to MPP Licensee Supply. Licensee's right to source Compound and/or Licensed Product from, or sell Compound and/or Licensed Product to, a particular MPP Licensee hereunder shall remain in effect solely for so long as such MPP Licensee remains compliant with the terms and conditions of its agreement with MPP, and provided that such agreement between such MPP Licensee and MPP has not expired or been terminated.
- 4.7 Disclosure Right. Licensee hereby grants MPP the right to disclose its contact information to Pfizer or an MPP Licensee for the fulfilment of this Section 4 ("**Disclosure Right**"). Licensee shall receive reciprocal information of other MPP Licensees to the extent that the Disclosure Right has been similarly granted by such MPP Licensees.
- 4.8 Anti-Competition. Licensee confirms and warrants that it shall not engage in any anti-competitive behavior if it exercises its rights under this Section 4 and shall be fully compliant of all Applicable Law. Licensee further represents, warrants and covenants that it shall not enter into any agreement or other arrangement with a supplier of ritonavir, materials used in the synthesis of the Compound, the Compound, Product and/or Licensed Product that would prioritize supply to Licensee or de-prioritize supply to Pfizer, or prevent, limit or otherwise restrict in any way (including, without limitation, as to amounts that may be purchased or pricing) such supplier from selling ritonavir, materials used in the synthesis of the Compound, the Compound, Product and/or Licensed Product to Pfizer.

## 5. NON-DIVERSION

- 5.1 Diversion. Licensee shall not, directly or indirectly, donate, distribute, sell, supply or otherwise make available Compound, Product and/or Licensed Product outside the Territory except as expressly permitted (and solely to the extent expressly permitted) under this Agreement. Without limitation of the foregoing, except to the extent provided under this Agreement, Licensee shall not, directly or indirectly, sell or supply:
- (a) Licensed Product, Product or the Compound outside the Territory where there is a Non-Territory Patent, for the duration of the relevant Non-Territory Patent;
  - (b) the Compound to any Third Party in the Territory that Licensee knows, believes or ought reasonably to suspect will sell or supply the Compound or use the Compound for manufacture of Product or Licensed Product for sale or supply outside the Territory where there is a Non-Territory Patent, for the duration of the relevant Non-Territory Patent;
  - (c) Product to any Third Party in the Territory that Licensee knows, believes or ought reasonably to suspect will sell or supply Product or use the Product for manufacture of Licensed Product for sale or supply outside the Territory where there is a Non-Territory Patent, for the duration of the relevant Non-Territory Patent; or
  - (d) Licensed Product to any Third Party in the Territory that Licensee knows, believes or ought reasonably to suspect will sell or supply Licensed Product outside the Territory where there is a Non-Territory Patent, for the duration of the relevant Non-Territory Patent.
- 5.2 Licensed Product Labelling. The labelling of all Licensed Products sold or offered for sale under this Agreement shall expressly state that:
- (a) the Licensed Product is manufactured under a license from the Medicines Patent Pool; and
  - (b) any other use, beyond the Field, is not authorized.
- 5.3 Notice to Third Parties. Licensee shall give written notice, prior to the first sale of Licensed Product, to any Third Party to which it sells Licensed Product of the restrictions contained in this Section 5, and Licensee shall use its best endeavors, without prejudice to any other provision of this Agreement, to ensure that such Third Parties will undertake to abide by the restrictions contained in this Section 5 and will assist the MPP and Pfizer in securing compliance with this Section 5 and the restrictions which it contemplates.



- 5.4 Breach. Licensee shall promptly notify MPP and Pfizer in writing of any breach or suspected breach of this Section 5 and shall take all reasonable steps to mitigate such breach.

## 6. INTELLECTUAL PROPERTY

- 6.1 Improvements License. Licensee shall disclose, promptly and in English, to MPP and Pfizer, without charge, any Improvements. As to any such Improvements, Licensee shall grant, and hereby does grant, to Pfizer, its Affiliates, and MPP a perpetual, irrevocable, worldwide, non-exclusive, transferable, and fully paid-up license, with the right to grant sublicenses through multiple tiers, under any and all Improvements (the “**Improvement License**”) for any and all purposes in the Pfizer Field, including the rights to use, have used, develop, have developed, manufacture, have manufactured, commercialize and have commercialized, offer for sale, sell, have sold, donate and distribute the Compound, Product and/or Licensed Product or any other product containing the Compound in the Pfizer Field. For the avoidance of doubt, the Improvement License shall not affect Licensee’s ownership of any such Improvements. MPP shall not sublicense the Improvement License to any Third Party or to another MPP Licensee without the consent of Licensee and Pfizer.
- 6.2 Out-of-Field License. Licensee shall grant, and hereby does grant, to Pfizer and its Affiliates a perpetual, irrevocable, worldwide, non-exclusive, transferable and fully paid-up license, with the right to grant sublicenses through multiple tiers, under any and all Improvements for any use outside of the Pfizer Field (the “**Out-of-Field License**”). Licensee shall grant, and hereby does grant, to Pfizer and its Affiliates an option and right of first refusal to obtain a sole, sublicensable, worldwide license under any and all Improvements for any use outside the Field on reasonable financial terms to be negotiated by Pfizer and Licensee (the “**Option and ROFR**”). For the avoidance of doubt, the Out-of-Field License and Option and ROFR shall not affect the Licensee’s ownership of any Improvements to the Licensed Product.
- 6.3 Patent Prosecution; Enforcement and Defense. Pfizer shall have the sole right (but not the obligation) to file, prosecute and maintain the Patents in the Territory in Pfizer’s name and at Pfizer’s own costs and expense. Pfizer will have the sole right (but not the obligation), at its own expense, to control enforcement and defense of the Patents and Licensed Know-How against any Third Party infringement or action, as applicable. If Licensee becomes aware of a possible infringement of the Patents by a Third Party in any country, Licensee will notify Pfizer, through MPP, immediately. The decision on whether any legal action is necessary or appropriate shall be made solely by Pfizer in its sole discretion. In the event that Pfizer institutes an action at its expense against alleged Third Party infringers with respect to Compound, Product or any Licensed Product, or takes action to defend the Patents, Licensee agrees to cooperate in good faith with Pfizer in such action, upon the request of Pfizer and Pfizer shall reimburse Licensee for the reasonable out-of-pocket costs incurred by Licensee in providing

such cooperation. Any recovery obtained by Pfizer as a result of such a proceeding or other action shall be retained by Pfizer.

- 6.4 Trademarks. No rights in any Pfizer Trademarks are granted to Licensee under this Agreement, and Licensee shall not appropriate or otherwise use, register to use or register any Pfizer Trademarks in connection with the Licensed Product in the Territory, including without limitation in connection with the sale, distribution, promotion, or marketing of the Licensed Product. A complete description of any trademark proposed to be used or registered by Licensee in connection with the sale of the Licensed Product in the Territory shall be submitted to MPP for Pfizer's written approval prior to use or filing an application to register such trademark. MPP shall promptly review such request and refer it to Pfizer. Licensee shall provide any additional information required by MPP in relation to such request. The response to Licensee for any request for approval shall be given within thirty (30) days of receipt by Pfizer from MPP of all relevant documentation necessary to consider Licensee's request. Such approval may be withheld if the subject trademark is determined by Pfizer, in its sole discretion, to be identical to or confusingly similar to any Pfizer Trademark; provided, however, that any such approval shall not waive any rights of Pfizer or its Affiliates with respect to the Pfizer Trademarks. Notwithstanding the foregoing, in reviewing and/or granting approval to Licensee for use of any trademark in connection with the sale of any Licensed Product, Licensee acknowledges and agrees that Pfizer shall have no obligation to assess the availability or validity of, or the ability of the Licensee to use, the proposed trademark or whether the proposed trademark is the same or is similar to any trademark proposed to be used by and/or approved by Pfizer for use by any other MPP Licensee in connection with the Compound or any Product or Licensed Product and Pfizer shall have no liability to Licensee where Licensee seeks to register or uses any trademark, logo or trade dress that is the same or similar to a that used by another MPP Licensee. In addition to the foregoing, for the avoidance of doubt, Licensee agrees that it shall not: (a) register, apply to register or, in connection with the sale of any Licensed Product, use any trademark, logo or trade name which is identical to or confusingly similar (as Pfizer shall determine in its sole discretion) to any Pfizer Trademark; (b) use trade dress, packaging (both internal and external), or labeling which is the same as or similar to (as Pfizer shall determine in its sole discretion) that of Pfizer or any Affiliate of Pfizer in connection with the sale of any Licensed Product; or (c) give the impression to the public, to physicians or to the trade that the Licensed Product is manufactured by or in any way connected with Pfizer or any of its Affiliates.

## 7. ROYALTY AND TAXES

- 7.1 No LIC Territory Royalty. No royalty shall be due and payable by Licensee for any sales of Licensed Product in any low-income country as designated in **Appendix 3** (the "LIC Territory").

- 7.2 Royalties. Subject to Section 7.3 of this Agreement, Licensee will pay to Pfizer an earned royalty at the rate of (a) five percent (5%) of aggregate Net Sales of Licensed Products sold by Licensee or its Affiliates to a Governmental Authority or Public Purchaser in each country in the Territory, other than the LIC Territory, during the Royalty Term, to the extent (i) a Valid Claim of Patent exists in the country of manufacture and/or sale of such Licensed Product or (ii) regulatory exclusivity exists for such Licensed Product in such country of sale, and (b) ten percent (10%) of aggregate Net Sales of Licensed Products sold by Licensee or its Affiliates to a commercial entity in a country in the Territory, other than the LIC Territory, during the Royalty Term, to the extent (i) a Valid Claim of Patent exists in the country of manufacture and/or sale of such Licensed Product or (ii) regulatory exclusivity exists for such Licensed Product in such country of sale, such royalties to be recorded in the manner further described in **Appendix 4** attached hereto.
- 7.3 Suspension of Royalty. Notwithstanding the foregoing, the royalty obligation with respect to all countries in the Territory shall be suspended until the end of the month in which the WHO declares the end of the Public Health Emergency of International Concern regarding COVID-19, and royalties shall only be payable as set forth in Section 7.2 of this Agreement with respect to any sales made by Licensee or its Affiliates thereafter.
- 7.4 Royalty Term. On a country-by-country and Licensed Product-by-Licensed Product basis, royalty payments in the Territory shall commence upon the first commercial sale of such Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an EUA or Key Approval, in such country in the Territory and will terminate upon the later of: (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in the country of sale or manufacture of such Licensed Product in the Territory or (b) expiration of regulatory exclusivity of such Licensed Product in such country of sale in the Territory (the “**Royalty Term**”).
- 7.5 Royalty Payments. Royalties accruing to Pfizer will be paid to Pfizer quarterly within forty-five (45) days after the end of each Agreement Quarter. Licensee will make all payments under this Agreement by wire transfer to an account of Pfizer designated by written notice from Pfizer. All royalties due to Pfizer will be payable in United States dollars. When Licensed Products are sold for monies other than United States dollars, the earned royalties will first be determined in the foreign currency of the country in which the sale was made and then converted into equivalent United States funds. The exchange rate will be that rate quoted in The Wall Street Journal on the last Business Day of the reporting period. Licensee shall bear the expense of any bank charges or any other transaction costs incurred in connection with payment under this Section 7 and will effect payment of such amount that will result in Pfizer receiving the full amount calculated for any payment with no deduction of any type. Each royalty payment shall be accompanied by a statement setting forth the elements and

calculation of the royalty amount in the format specified by Pfizer. For clarity, any sale of Compound, Product and/or Licensed Product between Licensee and other MPP Licensee(s) other than for end use by such other MPP Licensee(s) shall be exempt from any royalty payment.

#### 7.6 Taxes.

- (a) Payments due for sales occurring in any country outside the United States will not be reduced by any fees or other charges imposed by the Government of such country on the remittance of royalty income, provided that if laws or regulations require that taxes be withheld with respect to any royalty payments by Licensee to Pfizer under this Agreement, Licensee will: (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, (c) send evidence of the obligation together with proof of tax payment to Pfizer on a reasonable and timely basis following that tax payment, and (d) Licensee will reasonably assist Pfizer in seeking an exemption to such withholding to the extent available.
- (b) It is understood and agreed that any payments made under this Agreement are exclusive of any value added or similar tax (“**VAT**”), which shall be added thereon as applicable. In the event any payments made by Licensee to Pfizer pursuant to this Agreement become subject to withholding taxes under Applicable Law, Licensee shall deduct and withhold the amount of such taxes for the account of Pfizer to the extent required by Applicable Law and such amounts payable to the Pfizer shall be reduced by the amount of taxes deducted and withheld, which shall be treated as paid to Pfizer in accordance with this Agreement. To the extent that Licensee is required to deduct and withhold taxes on any payments under this Agreement, Licensee shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Pfizer an official tax certificate or other evidence of such withholding sufficient to enable Pfizer to claim such payments of taxes. Pfizer shall provide any tax forms to Licensee that may be reasonably necessary in order for Licensee not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Licensee shall provide Pfizer with reasonable assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit Pfizer.
- (c) Notwithstanding anything in this Agreement to the contrary, if an action, including, but not limited to, any assignment or transfer of its rights or obligations under this Agreement, or any failure to comply with Applicable Law or filing or record retention requirements (a “**Tax Action**”) by Licensee leads to the imposition of withholding tax liability or VAT on Pfizer that would not have been imposed in the absence of a

Tax Action or in an increase in such liability above the liability that would have been imposed in the absence of such Tax Action, then (i) the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Pfizer receives a sum equal to the sum which it would have received had no Tax Action occurred and (ii) the sum payable Licensee (in respect of which such deduction or withholding is required to be made) shall be made to Pfizer after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in accordance with Applicable Law. For the avoidance of doubt, Licensee shall only be liable for increased payments pursuant to this Section to the extent Licensee engaged in a Tax Action that created or increased a withholding tax or VAT on Pfizer.

- (d) Licensee agrees to cooperate and produce on a timely basis any tax forms or reports, including an IRS Form W-8BEN, reasonably requested by Pfizer in connection with any payment made by Licensee to Pfizer under this Agreement.

7.7 Interest. If monies owed to Pfizer under this Agreement are not received by Pfizer when due, Licensee will pay to Pfizer interest charges at a rate of three percent (3%) above the WSJ rate up to a maximum of ten percent (10%) per annum. Such interest will be calculated from the date payment was due until actually received by Pfizer. Such accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of Pfizer related to such late payment. Acceptance of any late payment will not constitute a waiver under Section 14.9 of this Agreement.

## **8. REPRESENTATIONS, WARRANTIES, AND COVENANTS**

8.1 Ability to Perform. Each of the Parties hereby represents and warrants that:

- (a) it is duly organized, validly existing and in good standing under the laws of the jurisdiction of their incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
- (b) this Agreement has been duly executed and delivered, and constitutes a legal, valid, and binding obligation, enforceable against it in accordance with the terms hereof;
- (c) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of any Governmental Authority having jurisdiction over such Party; and

- (d) it has not and will not employ or otherwise use in any capacity the services of any person or entity that is a Sanctions Target or is debarred by any Agency or the subject of debarment proceeding by any Agency in performing any activities under this Agreement. Each Party shall notify the other Party, in writing, immediately if any such sanctions or debarment occurs or comes to its attention, and shall, with respect to any person or entity so sanctioned or debarred, promptly remove such person or entity from performing any further activities under this Agreement, as applicable.

8.2 Additional Licensee Representations and Warranties. Licensee represents and warrants that:

- (a) all information provided by Licensee during the selection process, including information provided in the Expression of Interest system, is complete, truthful, and accurate in all respects;
- (b) it has the experience, ability and capacity to manufacture Licensed Product for the purposes of sale in the Territory; and
- (c) it has the experience, capability and capacity to Commercialize Licensed Product in the Territory.

8.3 Law Compliance

- (a) General. Licensee covenants and agrees that it shall perform all activities under this Agreement in accordance with all Applicable Law, including, without limitation, with respect to anti-corruption, anti-competition, recalls, safety and reporting requirements and export controls and sanctions, and shall obtain, have and maintain all necessary regulatory approvals (including, without limitation, Key Approvals), marketing authorizations, export licenses, and other permits and licenses, at Licensee's expense for the manufacture and sale of the Compound and/or Licensed Product and any other Licensee activities contemplated hereby. Licensee further agrees that it shall not export, re-export, transfer, transmit, or release (including to a foreign national within the United States and Germany) any goods, materials, software, or technology (including technical data) without first obtaining all necessary authorizations from the relevant Governmental Authorities. Notwithstanding anything herein to the contrary, any delay or failure to perform any part of this Agreement by either Party resulting from a denial, delay, or withdrawal of any required export authorization shall not constitute a breach of this Agreement nor expose either Party to liability hereunder.
- (b) Conflicts. Neither Party shall be required to take any action or perform any obligation under this Agreement to the extent that such action or

obligation is in direct conflict with, or penalizable under, any Applicable Law.

- 8.4 Trade Control Laws. The Parties shall comply with all applicable economic sanctions and export control laws in the performance of this Agreement, including without limitation the sanctions programs administered by the U.S. Department of Treasury's Office of Foreign Assets Control ("**OFAC**") and the Export Administration Regulations ("**EAR**") administered by the U.S. Department of Commerce's Bureau of Industry and Security ("**BIS**") (collectively "**Trade Control Laws**"). Licensee represents that neither Licensee nor, to the knowledge of Licensee, any director, officer, employee, or agent of Licensee, is an individual or entity ("**Person**") that is, or is fifty percent (50%) or more owned or controlled by Persons that are: (a) the target of any sanctions administered or enforced by the U.S. Government, including by OFAC, or by the governments of Switzerland, the EU, or the United Kingdom ("**Sanctions**") or listed on any denied party lists maintained by OFAC, BIS or on the European Union's Consolidated List of Persons, Groups and Entities Subject to EU Financial Sanctions, or (b) located, organized or resident in a country or territory that is, or whose government is, the target of Sanctions (including, without limitation, Cuba, Iran, North Korea, Crimea, Venezuela, and Syria) ((a) and (b) collectively, "**Sanctions Targets**").

Licensee further warrants that in relation to this Agreement it will not, directly or indirectly, use, transfer, sell, donate, lend, contribute or otherwise make available any rights (including intellectual property rights) or Know-How, or the Compound, Product, or Licensed Product, to any Sanctions Target, nor to any Person to engage in any activities or business of or with any Sanctions Target or in any country or territory, that, at the time of such transfer or other transaction, is, or whose government is, the target of Sanctions (including, for the avoidance of doubt, any country listed in **Appendix 3**) without prior written approval from MPP and Pfizer. Licensee covenants that it shall notify MPP and Pfizer in writing immediately if any of the preceding representations and warranties becomes incorrect during the term of this Agreement. In case of an inaccuracy or breach in the representations, warranties or covenants in this Section 8.4 during the term of this Agreement, MPP shall be entitled to terminate this Agreement immediately and without penalty to MPP.

Notwithstanding anything to the contrary in this Agreement, including **Appendix 3**, the Parties acknowledge that the grant of any rights or Know-How under this Agreement through Pfizer in the Pfizer-MPP Agreement relating to the Compound, Product or Licensed Product for, in, or to the Sanctions Targets require prior authorization, in the form of general licenses, specific licenses, and/or other authorizations, from OFAC and/or BIS. Accordingly, nothing in this Agreement, including **Appendix 3** shall be construed as a grant of rights or Know-How under this Agreement with respect to Sanctions Targets. MPP and Licensee shall, to the extent required, comply with applicable Trade Control Laws and shall not cause Pfizer to violate any applicable Trade Control Laws.

## 8.5 Ethical Business Practices.

- (a) By signing this Agreement, Licensee agrees to conduct the business contemplated herein in a manner which is consistent with both Applicable Law and good business ethics.
- (b) Specifically, Licensee warrants that none of the employees, agents, officers, or other members of the management of Licensee or its Affiliates or permitted assignees/transferees are or will become during the term of this Agreement Government Officials having governmental authority to make or participate in any decisions regarding the Licensed Product in the Territory. Licensee has not and shall not make any payment or promise of payment, either directly or indirectly, of money or any other thing of value, including but not limited to any compensation derived from this Agreement (hereinafter collectively referred to as a “**Payment**”), to Government Officials or representatives of other businesses or persons acting on behalf of any of the foregoing where such Payment would constitute a violation of any Applicable Law. In addition, regardless of legality, Licensee has not and shall not make any Payment either directly or indirectly to Government Officials if such Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of Licensee’s, MPP’s or Pfizer’s business.
- (c) Licensee has complied and shall comply with, and has not and will not cause its Affiliates, associates, directors, officers, shareholders, employees, representatives, or agents worldwide to be in violation with any applicable anti-corruption law or regulation and notably without limiting the foregoing to any provision of the United States Foreign Corrupt Practices Act (the “**FCPA**”) and U.K. Bribery Act 2010. In light of the aforementioned, Licensee has not and shall not, directly or indirectly, pay any money to, or offer or give anything of value to, any Government Official in order to obtain or retain business or to secure any commercial or financial advantage for Licensee, Pfizer or the MPP or any of their respective Affiliates. Licensee has not bribed and undertakes not to bribe Government Officials or any private companies or individuals, bribes having the following definition: offering, promising, or giving a financial or other advantage to another person where: (i) it is intended to bring about the improper performance of a relevant function or activity, or to reward such “Improper Performance” (as that term is used in the FCPA); or (ii) acceptance of the advantage offered, promised or given in itself constitutes improper performance of a relevant function or activity.
- (d) Licensee will maintain proper and accurate books, records, and accounts which accurately and fairly reflect any and all payments made, expenses incurred and assets disposed of in connection with its performance of this Agreement, and will maintain an internal accounting controls system to ensure the proper authorization, recording and reporting of all transactions



and to provide reasonable assurances that any breaches of this Section 8.5 will be prevented, detected and deterred.

- (e) Licensee further acknowledges that no employee of Pfizer and MPP or their respective Affiliates shall have the authority to give any direction, either written or oral, relating to any Payment by Licensee or its agents, employees, officers, subcontractors, sublicensees (for clarity, Licensee shall have no sublicensees under this Agreement), or Affiliates, to any Third Party in violation of this Agreement.
- (f) Licensee represents and warrants that it respects the human rights of its staff and does not employ child labor, forced labor, unsafe working conditions, or cruel or abusive disciplinary practices in the workplace and that it does not discriminate against any workers on any ground (including race, religion, disability, gender, sexual orientation or gender identity) and aims to achieve greater equity along those lines in the workplace; and that it pays each employee at least the minimum wage, provides each employee with all legally mandated benefits, and complies with the laws on working hours and employment rights in the countries in which it operates.
- (g) MPP may, in the event that it determines that Licensee has breached any provision of this Section 8.5, provide written notice to Licensee of its intention to terminate this Agreement, along with any evidence supporting its claim of breach (“**Breach**”) to the extent that it is possible to provide. The Parties will discuss any mitigation plans to the Breach but in the event that no consensus can be reached, MPP shall have the sole right to terminate this Agreement. These measures are in addition and without prejudice to any other remedies that may be available.
- (h) In addition to all other remedies and indemnities provided for in this Agreement, Licensee and its Affiliates shall indemnify and hold MPP and Pfizer and any of its Affiliates harmless from and against any and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that may arise by reason of the acts or omissions of Licensee or Third Parties acting on Licensee’s behalf which would constitute a violation of this Section 8.5.

8.6 Licensee Acknowledgement. Licensee acknowledges that Pfizer’s willingness to approve the selection of Licensee and execution of this Agreement is based, in part, upon the representations, warranties and covenants made by Licensee to MPP under this Agreement, which such representations, warranties and covenants constitute a material inducement for Pfizer’s approval of Licensee and this Agreement.

8.7 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE PFIZER-MPP AGREEMENT, MPP AND PFIZER

(IN THE PFIZER-MPP AGREEMENT) MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE PATENTS OR ANY LICENSE GRANTED BY MPP AND PFIZER (IN THE PFIZER-MPP AGREEMENT) HEREUNDER, OR WITH RESPECT TO THE COMPOUND, PRODUCT OR LICENSED PRODUCT, OR ANY OTHER MATTER. FURTHERMORE, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE PATENTS IS VALID OR ENFORCEABLE OR THAT THE MPP'S OR LICENSEE(S)'S USE OF THE PATENTS, LICENSED KNOW-HOW, COMPOUND, PRODUCT OR LICENSED PRODUCT AS CONTEMPLATED HEREUNDER WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. MPP AND PFIZER (IN THE PFIZER-MPP AGREEMENT) ALSO MAKE NO REPRESENTATION OR WARRANTY THAT LICENSEE(S)'S USE OF THE COMPOUND, PRODUCT OR LICENSED PRODUCT WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS (OTHER THAN THE PATENTS AND LICENSED KNOW-HOW) OF PFIZER OR ITS AFFILIATES. MPP AND PFIZER (IN THE PFIZER-MPP AGREEMENT) ALSO DO NOT GIVE ANY WARRANTY, EXPRESS OR IMPLIED, WITH REGARD TO THE SAFETY OR EFFICACY OF THE COMPOUND, PRODUCT OR LICENSED PRODUCT AND IT SHALL BE THE SOLE RESPONSIBILITY OF LICENSEE TO ENSURE SUCH SAFETY OR EFFICACY.

## **9. QUALITY CONTROL, REGULATORY COMPLIANCE, LIABILITY, AND INDEMNITY**

- 9.1 Quality Control; Regulatory Compliance. Licensee agrees that the Licensed Product sold by it and the processes for manufacturing, storage and handling of such Licensed Product shall strictly comply with all Applicable Law (including cGMP) and Licensee's manufacturing standards (such standards to be no less stringent than industry standards used by companies that manufacture similar products for sales in countries that are regulated by SRAs) relating to any operations involved in the manufacture, packaging, labeling, quality control, testing, receipt, storage of, warehousing, and shipping, of Licensed Product, including but not limited to regulations for protection of worker health and safety. Licensee shall immediately notify MPP in writing of any action (including any official notifications or communications) taken by any Agency in the Territory in connection with Licensee's failure to meet the standards set forth in this Section 9.1 for the manufacture and handling of the Licensed Product ("**Agency Action**"), such notice to set forth in reasonable detail all such failures and observations made by such Agency. If at any time, during the term of this Agreement, MPP is made aware of any Agency Action other than by Licensee pursuant to the preceding sentence, MPP shall promptly provide Licensee with a notice of the

same. Licensee shall within a period of thirty (30) days from becoming aware of an Agency Action provide MPP with a plan for remedying the same within a timeline to be mutually agreed by the Parties, such agreement by either Party not to be unreasonably withheld or delayed. If Licensee is unable to remedy the same within the mutually agreed timeline (or, in the absence of such a mutually agreed timeline, within a reasonable period of time not to exceed ninety (90) days), MPP may, after giving Licensee written notice, terminate this Agreement at its sole discretion and without prejudice to any other remedies that may be available to MPP; provided however, that in the event that Licensee has already received a prior notice of any such violation, then MPP shall have the right to terminate this Agreement immediately without any notice.

- 9.2 No MPP or Pfizer Liability. Neither Pfizer nor MPP shall be responsible to Licensee or to any Third Party for any damages or losses resulting, directly or indirectly from Licensee's or its Affiliates' or permitted assignees'/transferees' manufacture, packaging, labeling, receipt, shipping, handling, storage, use, importation, marketing, or sale of the Licensed Product or any other acts or omissions of Licensee arising out of this Agreement.
- 9.3 Indemnity. Licensee shall jointly and severally indemnify, hold harmless and defend MPP, Pfizer, inventors of any patents and patent applications within the Patents, its and their respective Affiliates, Third Parties to whom Pfizer, and each of their respective Affiliates may directly or indirectly owe an indemnity, and each of their respective directors, officers, employees, contractors and agents and its and their respective directors, officers, employees, contractors and agents (collectively, the "**Indemnitees**"), from and against any and all claims, demands, actions and proceedings (whether criminal or civil or in contract, tort or otherwise) ("**Claims**") for losses, damages, liabilities, costs and expenses (including, without limitation, attorneys' fees, witness fees, damages, judgments, fines, and amounts paid in settlement), and any amounts an Indemnitee becomes legally obligated to pay ("**Losses**"), directly or indirectly, arising out of, resulting from or related to: (a) the development (including, but not limited to, the conduct of any Clinical Trials), manufacture, use or sale of the Compound, Product or any Licensed Product by or on behalf of Licensee, its Affiliates and their respective directors, officers, employees, contractors and agents (including any product liability, liability for death, illness, personal injury, improper business practice or any other statutory liability or any other liability under any law or regulation to the extent arising or resulting therefrom), (b) any breach of the terms and conditions of this Agreement by Licensee, its Affiliates and their respective directors, officers, employees, contractors and agents, (c) any breach of any of the representations, warranties or covenants made by Licensee under this Agreement, (d) any negligence, recklessness or willful misconduct or wrongful intentional omissions of Licensee, its Affiliates and their respective directors, officers, employees, contractors and agents, (e) violation of Applicable Law by Licensee, its Affiliates and their respective directors, officers, employees, contractors and agents, (f) breach by Licensee of the scope of the licenses set forth in Sections 2.1 and 2.2 of this Agreement, or (g) the alleged or actual infringement or

misappropriation of any Third Party's intellectual property rights; provided, however, that the indemnification obligations set forth herein shall not apply to the extent such Losses directly result from the willful misconduct of the Pfizer Indemnitees.

In connection with any Claim for which an Indemnitee seeks indemnification from Licensee pursuant to this Agreement, such Indemnitee shall: (i) give Licensee prompt written notice of the Claim, provided that failure to provide such notice shall not relieve Licensee from its liability or obligation hereunder except to the extent of any material prejudice as a direct result of such failure; (ii) cooperate with Licensee, at Licensee's expense, in connection with the defense and settlement of the Claim; and (iii) permit Licensee to control the defense and settlement of the Claim, provided that Licensee may not settle the Claim without such Indemnitee's (and Pfizer's where Pfizer is not the Indemnitee) prior written consent, which shall not be reasonably withheld or delayed, in the event that such settlement admits wrongdoing on the part of any Indemnitee, admits that any Patent is invalid, unenforceable or not infringed or that imposes any financial obligations on Indemnitee or otherwise materially adversely impacts such Indemnitee's or Pfizer's rights or obligations. Further, such Indemnitee shall have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and its own expense. Notwithstanding the foregoing, Pfizer, directly or through any of its Affiliates, may elect to assume control of the defense of a Claim at any time if, in Pfizer's sole discretion: (A) Licensee fails to timely assume the defense of or reasonably defend such Claim in good faith to the satisfaction of Pfizer or its Affiliates; or (B) Pfizer or its Affiliates believes in good faith that a bona fide conflict exists between Indemnitee(s) and Pfizer with respect to such Claim. Upon written notice of such election, Pfizer shall have the right to assume control of such defense (directly or through either one of its Affiliate), and Licensee shall pay (as incurred and on demand), all Losses, including, without limitation, the reasonable attorneys' fees and other expenses incurred by Indemnitee(s), in connection with the Claim. In all events, Licensee shall cooperate with Indemnitee(s) in the defense, settlement or compromise of the Indemnified Claim.

Costs and expenses, including, without limitation, fees and disbursements of counsel, incurred by the Indemnitee(s) in connection with any Claim shall be reimbursed on a quarterly basis by Licensee, without prejudice to Licensee's right to refund in the event that Licensee is ultimately held in a final, non-appealable judgment or award to be not obligated to indemnify the Indemnitee(s).

- 9.4 Assumption of Liability. Notwithstanding any provision in this Agreement to the contrary, Licensee shall be solely responsible for any product liability, liability for death, illness, personal injury, improper business practice or any other statutory liability or any other liability under any law or regulation in respect of the Compound, Product and/or Licensed Product.

- 9.5 Insurance Recovery. Notwithstanding anything expressed or implied to the contrary in this clause, the amount of any losses subject to indemnification shall be reduced by the amount of any insurance proceeds received by the Indemnified Party from Licensee's insurer with respect to such Losses, and there shall be no obligation under this Agreement for Licensee to indemnify such Indemnified Party for the amount of losses so reduced by such payment by Licensee's insurer to such Indemnified Party.
- 9.6 LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT OR THE PFIZER-MPP AGREEMENT, IN NO EVENT SHALL PFIZER, MPP OR ANY OF THEIR RESPECTIVE AFFILIATES BE LIABLE TO LICENSEE FOR ANY DAMAGES, WHETHER CHARACTERIZED AS DIRECT OR INDIRECT DAMAGES, INCLUDING, BUT NOT LIMITED TO, ANY SPECIAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF BUSINESS OR PROFITS), RELATED TO THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, AND NEITHER PFIZER NOR MPP NOR ANY OF THEIR RESPECTIVE AFFILIATES SHALL HAVE ANY RESPONSIBILITIES OR LIABILITIES WHATSOEVER WITH RESPECT TO PATENTS, LICENSED KNOW-HOW, COMPOUND, PRODUCT OR LICENSED PRODUCT, EVEN IF, IN ANY SUCH CASE, LICENSEE IS ADVISED OF THE POSSIBILITY OF SUCH CLAIMS OR DEMANDS, REGARDLESS OF THE FORM OF ACTION OR LEGAL THEORY, WHETHER UNDER CONTRACT LAW, TORT LAW (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE), STRICT LIABILITY, STATUTE, WARRANTY OR OTHERWISE. IN NO INSTANCE SHALL PFIZER, MPP OR ANY OF THEIR RESPECTIVE AFFILIATES BE LIABLE TO LICENSEE (WHETHER ARISING IN WARRANTY, TORT (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE), CONTRACT, STRICT LIABILITY OR OTHERWISE) FOR ANY LIABILITIES OF LICENSEE TO ANY THIRD PARTY, INCLUDING, WITHOUT LIMITATION, THROUGH CONTRIBUTION, INDEMNITY, OR FOR ANY CLAIM FOR WHICH LICENSEE WOULD HAVE TO INDEMNIFY PFIZER OR MPP IF THAT CLAIM WERE BROUGHT DIRECTLY AGAINST PFIZER OR MPP.

## 10. INSURANCE

- 10.1 Pre-Clinical General Liability. Licensee, at its sole cost and expense, shall insure its activities in connection with this Agreement and obtain, keep in force, and maintain comprehensive or commercial form general liability insurance (contractual liability included) with limits as follows:
- (a) Each occurrence \$500,000
  - (b) Products/completed operations aggregate \$1,000,000
  - (c) Personal and advertising injury \$500,000
  - (d) General aggregate (commercial form only) \$1,000,000

- 10.2 Clinical General Liability. Notwithstanding the foregoing, no later than sixty (60) days before the first use of any Licensed Product in or on a human, Licensee, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force, and maintain comprehensive or commercial form general liability insurance (contractual liability included) with limits as follows:
- (a) Each occurrence \$10,000,000
  - (b) Products/completed operations aggregate \$10,000,000
  - (c) Personal and advertising injury \$1,000,000
  - (d) General aggregate (commercial form only) \$5,000,000
- 10.3 Marketing General Liability. Notwithstanding the foregoing, no later than sixty (60) days before the anticipated date of market introduction of any Licensed Product, whether such market introduction is made under an EUA or Key Approval, Licensee, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force, and maintain comprehensive or commercial form general liability insurance (contractual liability included) with limits as follows:
- (a) Each occurrence \$10,000,000
  - (b) Products/completed operations aggregate \$50,000,000
  - (c) Personal and advertising injury \$5,000,000
  - (d) General aggregate (commercial form only) \$10,000,000
- 10.4 Term. If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement.
- 10.5 Policy Conditions. Sublicensee's insurance obligations can be met through a combination of insurance or self-insurance. The coverage and limits referred to in Sections 10.1 through 10.3 of this Agreement will not in any way limit the liability of Licensee under this Agreement. Upon the execution of this Agreement, subsequently at the time of each of the further triggers stated above requiring increased coverage, Licensee will furnish MPP with certificates of insurance evidencing compliance with all requirements herein. Pfizer shall be named as an additional insured on each insurance policy. Licensee will promptly notify MPP of any material modification of the insurance coverages or cancellation notice it receives of any such insurance policies. All insurance coverage required under this Agreement shall be primary to any coverage carried by Pfizer or MPP. Pfizer, the MPP and their respective Affiliates, and their respective directors, officers, agents, and employees will be named as loss payees under such commercial general liability and product liability insurance. Upon request by MPP or Pfizer, Licensee shall provide to Pfizer and MPP evidence of its insurance coverage.

## 11. STATEMENTS, REPORTING AND RIGHT TO AUDIT

- 11.1 Books and Records; Audit Right. Licensee will keep full, true, and accurate books and records containing all particulars that may be necessary for the purpose of showing the amount of royalties payable to Pfizer and Licensee's compliance with other obligations under this Agreement and Applicable Law. Said books and records will be kept at Licensee's principal place of business or the principal place of business of the appropriate division of Licensee to which this Agreement relates. Said books and records and the supporting data will be open at all reasonable times during normal business hours upon at least fifteen (15) days' advance written notice, for five (5) years following the end of the calendar year to which they pertain, to the inspection and audit (on site if Licensee so requests) by independent certified public accountants hired by Pfizer and MPP, individually or together and reasonably acceptable to Licensee for the purpose of verifying Licensee's royalty reports or compliance in other respects with this Agreement and Applicable Law. Such certified public accountants will be bound to hold all information in confidence except as necessary to communicate Licensee's non-compliance with this Agreement to Pfizer and/or MPP. The fees and expenses of the certified public accountants performing such an examination will be borne by Pfizer and/or MPP. However, if an error in underpaid royalties to Pfizer of more than five percent (5%) of the total royalties due for any year is discovered, then the fees and expenses of these representatives will be borne by Licensee.
- 11.2 Royalty Reporting. After the first sale anywhere in the Territory, within twenty (20) Business Days following the end of each Agreement Quarter, Licensee shall deliver to MPP a statement accounting for, *inter alia*, all royalties calculations, Licensed Products, Products and/or Compound (in terms of smallest units and patient packs for each formulation) sold or supplied by Licensee under this Agreement during such Agreement Quarter in the Reporting Template as set forth in **Appendix 4**. For the avoidance of doubt, such royalty reports shall include sales for which no royalty payment may be due and payable. MPP agrees that information contained in quarterly and other such reports shall be treated as Confidential Information, provided, however, that such information may be shared with Pfizer (with Pfizer treating such reports as Confidential Information).

## 12. TERM AND TERMINATION

- 12.1 Term. Unless otherwise terminated by the operation of law or by acts of the Parties in accordance with the terms of this Agreement, this Agreement will be in force from the Effective Date and will remain in effect on a country-by-country basis until the later of (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in both the country of sale and the country of manufacture of a Licensed Product (including, without limitation, the manufacture of Compound or Product contained in such Licensed Product) or (b) expiration of the last regulatory exclusivity for a Licensed Product in a country of sale of such Licensed Product.

- 12.2 Termination for Breach. A Party (“**non-breaching party**”) shall have the right to terminate this Agreement in the event the other Party (“**breaching party**”) is in material breach of any of its material obligations under this Agreement. The non-breaching party shall provide written notice to the breaching party. The breaching party shall have a period of thirty (30) days after such written notice is provided to cure such breach, or to provide a timeline to cure such breach to the satisfaction of the non-breaching party. If such breach is not cured within the 30-day period or in accordance with the timeline, the non-breaching party shall have the right to terminate this Agreement immediately in the sole discretion. Any termination pursuant to this Section 12.2 will not (a) relieve either Party of any obligation or liability accrued; (b) impair any accrued rights of either Party; or (c) rescind anything done by either Party hereunder prior to the time of such termination becoming effective. In the case where the breaching party is Licensee, such termination shall not relieve Licensee of its obligation to pay any royalty or other fees owing at the time of such termination.
- 12.3 MPP Right to Terminate. MPP shall have the right to terminate this Agreement, either in whole or in relation to a particular Patent, with immediate effect by notice in writing to Licensee if:
- (a) Licensee breaches any of the anti-diversion provisions of Section 5 of this Agreement;
  - (b) MPP becomes aware of any action (including any official notifications or communications) taken by any Agency involving a determination of Licensee’s failure to comply with cGMP in connection with for the manufacture and handling of the Licensed Products, or otherwise reasonably determines that, due to material deficiencies in Licensee’s compliance, or repeated failure to comply, with the quality requirements of Section 9.1, Licensee is unable to reliably and consistently manufacture Compound or Licensed Product in accordance with such quality requirements;
  - (c) Licensee fails to comply with the obligations contained in Section 3.7 of this Agreement;
  - (d) Licensee fails to comply with the obligations contained in Section 3.12 of this Agreement;
  - (e) Licensee repeatedly fails to comply with, or to timely provide MPP with the reports contemplated under this Agreement, including, but not limited to, the reports required under Sections 3.4, 3.8, 3.9, 4.5 and 11.2 of this Agreement;
  - (f) Licensee fails to file for WHO Prequalification of the Licensed Product within six (6) months of a WHO Expression of Interest for the Licensed Product or such other time as may be mutually agreed between the Parties;



- (g) any material safety issue that Pfizer or MPP reasonably believes makes it inadvisable to proceed or continue with the Commercialization of Licensed Product in the Territory;
- (h) the legal or beneficial ownership of Licensee or any of its Affiliates changes, directly or indirectly, without the prior written consent of Pfizer and MPP in accordance with Section 14.8;
- (i) any serious or intentional violation of any Applicable Law or misappropriation of a Third Party's intellectual property rights by Licensee anywhere in the world, which in Pfizer's and MPP's judgement, may reflect unfavorably on Pfizer, MPP, their reputation or Licensed Product; or
- (j) Licensee is in breach of Section 8.3, Section 8.4 or Section 8.5 of this Agreement.

12.4 Failure to Promote Access. If, in the reasonable opinion of the MPP, Licensee fails to promote access or appears in MPP's reasonable opinion, will fail to promote access to the Licensed Products in the Territory in accordance with this Agreement, the MPP shall give notice to Licensee requiring it to cure such failure. If, in the reasonable opinion of the MPP, Licensee fails to present an acceptable plan within sixty (60) days and report reasonable progress within one hundred eighty (180) days after receiving written notice with respect to the default, the MPP shall have the right to terminate this Agreement with immediate effect by giving written notice to Licensee. In making such determination of reasonable progress, the MPP shall take into account the period within which the relevant authorities provide the necessary approvals and normal development lead time for the Licensed Products, and progress reported by Licensee in its quarterly reports and meetings provided under Section 3.8 of this Agreement.

12.5 Misrepresentations in Expression of Interest. Licensee acknowledges that it was offered to enter into this Agreement on the basis of certain representations and projections that it made through MPP's Expression of Interest system. In the event that MPP discovers any material misrepresentations made therein, or if Licensee fails to substantially meet its projections (including, without limitation, projections regarding the countries in which Licensee intends to Commercialize Licensed Product, the efforts and resources that Licensee intends to devote to the Commercialization of Licensed Product in each country and the extent to which Licensee's supply is sufficient to meet demand in each country), MPP shall have the right, upon thirty (30) days' notice, to terminate this Agreement.

12.6 Conversion to Direct License with Pfizer. Subject always to the termination provisions of the Pfizer-MPP Agreement, in the event that the Pfizer-MPP Agreement is terminated prior to its Term, this Agreement shall be converted into a direct license between Pfizer and Licensee, provided that (a) Licensee is in good standing under, and not in breach of, this Agreement, (b) Pfizer reserves its rights

to terminate this Agreement on the same grounds as those having led to termination of the Pfizer-MPP Agreement or pursuant to any rights of termination specified in this Agreement and (c) the terms of this Agreement (as converted) shall be no more onerous upon Pfizer than the terms of the Pfizer-MPP Agreement. In the event of such conversion and upon Pfizer's request, Licensee shall agree in writing to such conversion and to perform all of its obligations under such direct license.

- 12.7 Termination by Licensee. Licensee may terminate this Agreement at any time by providing thirty (30) days written notice to MPP. Any termination pursuant to this Section 12.7 by Licensee will not relieve Licensee of any obligation or liability accrued hereunder prior to such termination or rescind anything done by Licensee or any payments made to Pfizer hereunder prior to the time such termination becomes effective, and such termination will not affect in any manner any rights of MPP arising under this Agreement prior to such termination.
- 12.8 Insolvency. Either Party may terminate this Agreement in the event that the other Party becomes insolvent, makes an assignment to the benefit of creditors, or has a petition in bankruptcy filed for or against it.
- 12.9 Effects of Termination. Upon termination of this Agreement other than expiration of this Agreement pursuant to Section 12.1 of this Agreement, (a) all rights and licenses granted to Licensee under Section 2 of this Agreement shall terminate and Licensee shall cease all use of the Patents and the Licensed Know-How, (b) the Parties will cooperate with each other to provide for an orderly wind-down of the transactions contemplated herein and (c) Pfizer shall have the right to purchase from Licensee ritonavir, materials used in the synthesis of the Compound, the Compound, Product and/or Licensed Product at the actual cost of goods (verifiable via Third Party audit) plus a ten percent (10%) markup under a supply agreement containing such other reasonable and customary terms and conditions as are agreed by Pfizer and Licensee in good faith. Any termination or expiration of this Agreement will not relieve Licensee of its obligations to pay any monies due or owing at the time of such termination and will not relieve any obligations, of either to the other Party, established prior to termination.
- 12.10 Survival. Sections 1, 2.3, 2.7 (with respect to Licensee's responsibility and liability for its Affiliates), 2.8, 3.3 (with respect to Licensee's indemnity obligation), 3.4, 3.12, 3.13, 3.14, 4.4 (with respect to the last sentence), 4.8, 6.1, 6.2, 7 (with respect to any sales of Licensed Product sold or manufactured prior to termination), 8.7, 9.2, 9.3, 9.4, 9.5, 9.6, 10 (for the period set forth in Section 10.4), 11.1 (for the period set forth therein), 11.2 (with respect to any sales of Licensed Product sold or manufactured prior to termination), 12.9, 13, 14 and this Section 12.10 shall survive termination or expiry of this Agreement.

### 13. CONFIDENTIALITY AND PUBLICATIONS

- 13.1 Confidential Information. Each Party agrees to keep secret and confidential any and all business information, Know-How, quarterly reports, technology, or any other confidential information disclosed by one Party or Pfizer (“**Confidential Information**”) to the other Party pursuant to this Agreement (including any discussions or correspondence relating to the preparation of this Agreement), and not to disclose such information to any Third Party other than to (a) Pfizer in order to comply with the Pfizer-MPP Agreement and (b) any Agency as may be required by Applicable Law. For the avoidance of doubt, Pfizer shall have the right to such Confidential Information and wherever Pfizer has a contractual obligation towards a Third Party to disclose information regarding the Licensed Product or Compound, Pfizer may disclose Confidential Information to that Third Party under obligations of confidentiality no less stringent than contained herein. The obligations imposed by this Section 13.1 shall not apply to any information that the receiving Party can demonstrate by competent written evidence:
- (a) is known by the receiving Party at the time of its receipt and, not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records;
  - (b) is in the public domain other than as a result of any breach of this Agreement by the receiving Party;
  - (c) is subsequently disclosed to the receiving Party on a non-confidential basis by a Third Party who may lawfully do so; or
  - (d) is independently discovered or developed by the receiving Party without the use of, or reference to, Confidential Information of the disclosing Party, as documented by the receiving Party’s business records.
- 13.2 Licensed Know-How. Licensee will keep Licensed Know-How confidential subject to Section 13.1 of this Agreement.
- 13.3 Return and Destruction. Within thirty (30) days after any expiration or termination of this Agreement, either Party shall destroy (and certify to the other Party such destruction) or return all Confidential Information provided by the other Party except as otherwise set forth in this Agreement. One copy of the other Party’s Confidential Information may be retained solely for archival purposes as a means of determining any continuing or surviving obligations under this Agreement.
- 13.4 Confidentiality Term. The obligations of confidentiality set forth in this Section 13 shall survive for a period of ten (10) years after the expiration, cancellation, or other termination of this Agreement.
- 13.5 No Public Statements. Subject always to MPP’s obligations under the Pfizer-MPP Agreement, MPP and Licensee agree that no public release or

announcement concerning this Agreement shall be issued without the prior written consent of MPP and Pfizer, except if such release or announcement may be required by law (including without limitation information to any Agency), in which case Licensee shall allow Pfizer reasonable time to comment on such release or announcement in advance of such issuance.

#### 14. MISCELLANEOUS

- 14.1 Third Party Beneficiary. The Parties acknowledge and agree that Pfizer is intended to be and constitutes a third-party beneficiary of the representation, warranties, covenants, and agreements of Licensee, and Pfizer is entitled to enforce, without any obligation to consult with, or obtain approval from, MPP, the terms and provisions of this Agreement on its own behalf to the same extent as MPP, including, without limitation, any termination right that MPP may have hereunder. In no event shall Pfizer be deemed a party to this Agreement.
- 14.2 Agency. Neither Party is, nor will be deemed to be, an employee, agent or representative of the other Party for any purpose. Each Party is an independent contractor, not an employee or partner of the other Party. Neither Party shall have the authority to speak for, represent or obligate the other Party in any way without prior written authority from the other Party.
- 14.3 Entire Understanding. This Agreement embodies the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof. In each instance under this Agreement where Pfizer's consent, approval, permission, acquiescence or other form of acceptance is required ("**Pfizer Consent Right**"), it shall be read and understood to mean that Pfizer may withhold such Pfizer Consent Right at its sole and absolute discretion unless a contrary standard is expressly stated therein with respect to such Pfizer Consent Right.
- 14.4 Severability. The Parties hereby expressly state that it is not their intention to violate any applicable rule, law, or regulation. If any of the provisions of this Agreement are held to be void or unenforceable with regard to any particular country by a court of competent jurisdiction, then, to the extent possible, such void or unenforceable provision shall be replaced by a valid and enforceable provision which will achieve as far as possible the economic business intentions of the Parties. The provisions held to be void or unenforceable shall remain, however, in full force and effect with regard to all other countries. All other provisions of this Agreement shall remain in full force and effect.
- 14.5 Notices.
- (a) Any legal notice or other communication to be given under this Agreement, unless otherwise specified, shall be in writing and shall be deemed to have been provided when delivered to the addressee at the

address listed below (i) on the date of delivery if delivered in person or email (receipt confirmed) or (ii) three days after mailing by registered or certified mail, postage paid:

In the case of MPP:

Medicines Patent Pool  
Rue de Varembé 7  
Geneva 1202  
Switzerland  
Attention: General Counsel  
E-mail:

In the case of Licensee:

\_\_\_\_\_  
\_\_\_\_\_  
Attention:  
E-mail:

- (b) Any Party may change its address for communications by a notice in writing to the other Party in accordance with this Section.

14.6 Language; Governing Law. This Agreement is entered into and will be governed by and construed in accordance with the English language. This Agreement is made in accordance with and shall be governed and construed under the laws of New York, New York, USA, without regard to its choice of law principles.

14.7 Dispute Resolution.

- (a) The Parties agree that in the event of a dispute they shall first attempt in good faith to resolve such dispute.
- (b) In the event that such dispute is not resolved on an informal basis, either Party may refer the dispute to the Executive Director of the MPP, and to \_\_\_\_\_ of Licensee (together, the “**Designated Officers**”).
- (c) In the event that is not resolved by the Designated Officers within thirty (30) days after submission to such Designated Officers, each Party shall have the right to submit such dispute (except for any intellectual property matter disputes) to non-binding mediation in accordance with the WIPO Mediation Rules.
- (d) In the event that such dispute is not resolved within thirty (30) days following submission to such non-binding mediation, each Party shall have the right to submit such dispute (except for any intellectual property

disputes) to final and binding arbitration. The arbitration shall be conducted by three (3) arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce (“ICC”). The claimant shall nominate an arbitrator in its request for arbitration. The respondent shall nominate an arbitrator within thirty (30) days of the receipt of the request for arbitration. The two (2) arbitrators nominated by the Parties shall nominate a third arbitrator, in consultation with the Parties, within thirty (30) days after the confirmation of the later-nominated arbitrator. The third arbitrator shall act as chair of the tribunal. If any of the three (3) arbitrators are not nominated within the time prescribed above, then the ICC shall appoint the arbitrator(s). The seat of the arbitration shall be New York, New York, USA, and it shall be conducted in the English language. The Parties undertake to maintain confidentiality as to all aspects of the arbitration, including its existence, content and result, and as to all submissions, correspondence and evidence relating to the arbitration proceedings. The foregoing sentence shall survive the termination of the arbitral proceedings. Notwithstanding the foregoing, a Party may disclose information relating to the arbitration proceedings to the extent that disclosure is required to: (a) protect or pursue a legal right related to the arbitration; (b) enforce or challenge an award in bona fide legal proceedings; (c) respond to a bona fide compulsory order or request for information of a Governmental Authority or Agency; (d) make a disclosure required by securities laws, rules of a securities exchange, or other similar laws, regulations, or rules; or (e) seek legal, accounting, or other professional services. The costs of the arbitration, including, without limitation, the Parties’ reasonable legal fees, shall be borne by the unsuccessful Party. However, the arbitral tribunal may apportion such costs between the Parties if it determines that apportionment is reasonable, taking into account the circumstances of the case. The arbitration award shall be final and binding on the Parties, and the Parties undertake to carry out any award without delay. Judgment upon the award may be entered by any court having jurisdiction of the award or having jurisdiction over the relevant Party or its assets.

- (e) The foregoing however shall not prevent a Party from seeking and obtaining injunctive relief at any time if in its judgment such action is necessary to avoid irreparable harm. The Parties expressly and irrevocably submit to the jurisdiction of the court of New York, New York, USA for any such injunctive relief.
- (f) Without prejudice to the foregoing, nothing in this Agreement shall prevent or restrict MPP or Pfizer from electing to bring proceedings in relation to patent infringement or from applying for injunctive relief in any country outside the United States, to which election MPP and Licensee hereby agrees.

- (g) The requirement to attempt to resolve a dispute in accordance with this Section 14.7 of this Agreement does not affect a Party's right to terminate this Agreement as provided in Section 12 of this Agreement, and neither Party shall be required to follow these procedures prior to terminating this Agreement.
  - (h) In the event that Pfizer elects to enforce any rights of MPP under this Section 14.7 pursuant to Section 14.1 of this Agreement, or, in the event that Licensee has any dispute involving, in whole or in part, Pfizer, then, without implying any obligation or liability of Pfizer under this Agreement or waiving any of its potential defenses, including, but not limited to, any defense regarding a lack of contractual privity between Licensee and Pfizer, the terms and conditions of this Section 14.7 shall apply. The Designated Officer for Pfizer shall be Pfizer Inc.'s Senior Vice President, Business Development.
- 14.8 Assignment. Neither Party is entitled to transfer or assign this Agreement or the rights and obligations under this Agreement without the other Party's and Pfizer's prior written consent. For the avoidance of doubt, Pfizer, as a third party beneficiary, shall have the right to assign, or transfer its benefits and rights under this Agreement or any part thereof without the prior written consent of MPP or Licensee. Any attempted assignment or delegation in violation of this Section 14.8 shall be null and void. Subject to the foregoing, this Agreement will inure to the benefit of, and be binding on, the Parties' successors and assigns.
- 14.9 Amendments and Waivers. No amendment or modification hereof shall be valid or binding upon the Parties unless made in writing and signed by both Parties and consented to in writing by Pfizer. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver; provided, however, that no waiver by MPP shall be effective unless consent to in writing by Pfizer. No waiver by any Party in one or more instances of any of the provisions of this Agreement or the breach thereof shall establish a precedent for any other instance with respect to the same or any other provision. Furthermore, in case of waiver of a particular provision, all other provisions of this Agreement shall continue in full force and effect.
- 14.10 Entire Agreement. This Agreement, together with its Appendixes, contains the entire agreement between the Parties in respect of the subject matter hereof, and supersedes and cancels all previous agreements, negotiations, commitments, and writings in respect of the subject matter hereof, except that any previous confidentiality agreements shall remain in full force and effect.
- 14.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.

- 14.12 Privacy Laws. Licensee and MPP shall comply with all Applicable Law relating to data privacy, personal data, trans-border data flow, and data protection involved in handling any personal data and information related to each other and their representatives. It shall be the duty of Licensee and MPP to ensure that no personally identifiable information that permits the identity of an individual to whom the information applies to be reasonably inferred by either direct or indirect means is shared with each other under any circumstances. This obligation shall survive the expiry of this Agreement.
- 14.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument. Signature pages of this Agreement may be exchanged by facsimile, pdf, or through DocuSign, and that any such e-signature shall be given the same legal force and effect as the physical delivery of this Agreement, bearing original handwritten signatures without affecting the validity thereof.

*[signatures appear on following page]*



IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

*MEDICINES PATENT POOL:*

**Medicines Patent Pool**


By \_\_\_\_\_  
Name:  
Title:

*LICENSEE:*

\_\_\_\_\_  
By \_\_\_\_\_  
Name:  
Title:

## Appendix 1

### Compound



## Appendix 2

### Patents

Country	Patent Type	Status	App No.	Filing Date	Title
<a href="#">A.R.I.P.O.</a>	Compound	Filed	<a href="#">AP/P/2021/013602</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Algeria</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Argentina</a>	Compound	Filed	<a href="#">P210102205</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Aruba</a>	Compound	Filed	<a href="#">Awaiting</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Australia</a>	Compound	Filed	<a href="#">2021266232</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bahamas</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">Bahrain</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bangladesh</a>	Compound	Filed	<a href="#">248/2021</a>	08-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Barbados</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Bolivia</a>	Compound	Filed	<a href="#">SP-000165-2021</a>	09-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Brazil</a>	Compound	Filed	<a href="#">BR112021022419-0</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Canada</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Chile</a>	Compound	Filed	<a href="#">202102965</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">China P.R.</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Colombia</a>	Compound	Filed	<a href="#">NC2021/0015067</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Costa Rica</a>	Compound	Filed	<a href="#">2021-0558</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Cuba</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Dominican Republic</a>	Compound	Filed	<a href="#">P2021-0232</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Ecuador</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Egypt</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">El Salvador</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Eurasian Patent Convention</a>	Compound	Filed	<a href="#">202192798</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">European Patent Convention</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Georgia</a>	Compound	Filed	<a href="#">15794/1</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Guatemala</a>	Compound	Filed	<a href="#">A-2021-00229</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Honduras</a>	Compound	Filed	<a href="#">HN/P/2021/002695</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Hong Kong</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">India</a>	Compound	Filed	<a href="#">202117051620</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Indonesia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Israel</a>	Compound	Filed	<a href="#">287880</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Japan</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Korea South</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Kosovo</a>	Compound	Filed	<a href="#">KS/P/2021/12</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Kuwait</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Lebanon</a>	Compound	Filed	<a href="#">12283</a>	26-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Macao</a>	Compound	Docketed			Nitrile-Containing Antiviral Compounds
<a href="#">Malaysia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Mexico</a>	Compound	Filed	<a href="#">MX/a/2021/013679</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Mongolia</a>	Compound	Filed	<a href="#">10-2021-0006800</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">New Zealand</a>	Compound	Filed	<a href="#">782196</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Nicaragua</a>	Compound	Filed	<a href="#">2021-000104-I</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Nigeria</a>	Compound	Filed	<a href="#">280526413368</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">O.A.P.I.</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Oman</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Pakistan</a>	Compound	Filed	<a href="#">Awaiting</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Panama</a>	Compound	Filed	<a href="#">93684-01</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Paraguay</a>	Compound	Filed	<a href="#">65555/2021</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Patent Cooperation Treaty</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Peru</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Philippines</a>	Compound	Filed	<a href="#">1-2021-552851</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Qatar</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Russian Federation</a>	Compound	Filed	<a href="#">2021132570</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Saudi Arabia</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Singapore</a>	Compound	Filed	<a href="#">11202112508R</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">South Africa</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Sri Lanka</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Taiwan</a>	Compound	Filed	<a href="#">110129119</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds

Country	Patent Type	Status	App No.	Filing Date	Title
<a href="#">Thailand</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Trinidad &amp; Tobago</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Ukraine</a>	Compound	Filed	<a href="#">a 2021 06382</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United Arab Emirates</a>	Compound	Filed	<a href="#">P6002051/2021</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Filed	<a href="#">17/395139</a>	05-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/170158</a>	02-Apr-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/073982</a>	03-Sep-2020	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/194241</a>	28-May-2021	Nitrile-Containing Antiviral Compounds
<a href="#">United States</a>	Compound	Inactive	<a href="#">63/143435</a>	29-Jan-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Uruguay</a>	Compound	Filed	<a href="#">39372</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Uzbekistan</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Venezuela</a>	Compound	Filed	<a href="#">Awaiting</a>	19-Aug-2021	Nitrile-Containing Antiviral Compounds
<a href="#">Vietnam</a>	Compound	Filed	<a href="#">PCT/IB2021/057281</a>	06-Aug-2021	Nitrile-Containing Antiviral Compounds

All of the Patents are owned by Pfizer Inc. as of the effective date of the Pfizer-MPP Agreement.

### Appendix 3

#### Territory

LIC : Low-Income Country  
 LMIC : Lower Middle-Income Country  
 UMIC : Upper Middle-Income Country

Country	Classification
Afghanistan	LIC
Algeria	LMIC
Angola	LMIC
Armenia	UMIC
Bangladesh	LMIC
Belize	UMIC
Benin	LMIC
Bhutan	LMIC
Bolivia	LMIC
Botswana	UMIC
Burkina Faso	LIC
Burundi	LIC
Cabo Verde	LMIC
Cambodia	LMIC
Cameroon	LMIC
Central African Republic	LIC
Chad	LIC
Comoros	LMIC
Congo, Dem. Rep.	LIC
Congo, Rep.	LMIC
Côte d'Ivoire	LMIC
Djibouti	LMIC
Egypt, Arab Rep.	LMIC
El Salvador	LMIC
Equatorial Guinea	UMIC
Eritrea	LIC
Eswatini	LMIC
Ethiopia	LIC
Gabon	UMIC
Gambia, The	LIC
Georgia	UMIC
Ghana	LMIC

Country	Classification
Guatemala	UMIC
Guinea	LIC
Guinea-Bissau	LIC
Haiti	LIC
Honduras	LMIC
India	LMIC
Indonesia	UMIC
Iran	UMIC
Jordan	UMIC
Kenya	LMIC
Kiribati	LMIC
Korea, Dem. People's Rep.	LIC
Kosovo	UMIC
Kyrgyz Republic	LMIC
Lao PDR	LMIC
Lesotho	LMIC
Liberia	LIC
Madagascar	LIC
Malawi	LIC
Mali	LIC
Mauritania	LMIC
Micronesia, Fed. Sts.	LMIC
Moldova	LMIC
Mongolia	LMIC
Morocco	LMIC
Mozambique	LIC
Myanmar	LMIC
Namibia	UMIC
Nepal	LMIC
Nicaragua	LMIC
Niger	LIC
Nigeria	LMIC
Pakistan	LMIC
Papua New Guinea	LMIC
Philippines	LMIC
Rwanda	LIC
Samoa	UMIC
São Tomé & Príncipe	LMIC
Senegal	LMIC
Sierra Leone	LIC

Country	Classification
Solomon Islands	LMIC
Somalia	LIC
South Africa (Public Market)	UMIC
South Sudan	LIC
Sri Lanka	LMIC
Sudan	LIC
Syrian Arab Republic	LIC
Tajikistan	LIC
Tanzania	LMIC
Timor-Leste	LMIC
Togo	LIC
Tonga	UMIC
Tunisia	LMIC
Uganda	LIC
Ukraine	LMIC
Uzbekistan	LMIC
Vanuatu	LMIC
Venezuela	UMIC
Vietnam	LMIC
West Bank and Gaza	LMIC
Yemen, Rep.	LIC
Zambia	LMIC
Zimbabwe	LMIC

## Appendix 4

### Quarterly Reporting Template

Each Reporting Template shall include the following but may be subject to change from time to time:

#### Reporting Template for Royalties

Country	Local Currency (LC)	Customer	Gross revenue from Sale of Licensed Products (in LC)	Allowable Deductions (in LC)	Net Sales pursuant to Section 1.21 of the License Agreement, itemized detail of details against gross sales to compute net sales (LC)	Exchange Rate (USD per LC)	Net Sales pursuant to Section 1.21 of the License Agreement, itemized Detail of details against gross Sales to compute net sales (LC)	Royalty Rate	Total Royalties due to Pfizer
E.g. India	INR	Gov. Entities/ Public Purchasers	80,000,000	5,000,000	75,000,000	0.0133	1,000,000	5%	50,000
	INR	Commercial Entities	20,000,000	1,000,000	19,000,000	0.0133	253,333.33	10%	25,333.33

Compliance Certification:	I hereby certify that all activities performed under the License Agreement have been conducted in accordance with all Applicable Law (as defined in the License Agreement), including, without limitation, with respect to anti-corruption, anti-competition, recalls, safety and reporting requirements, and export controls and sanctions.
	Name: _____ Date: _____ Title: _____

#### Reporting Template for Licensed Products

Country	Licensed Product manufactured and sold	Strength	Formulation (Tablet/granules /liquid/powder for suspension)	Pack Size	Quantity (number of packs)	Total Value in USD (FOB)*	Country of Origin

\* Please mention FOB (Free on Board) price basis country of origin  
 Note: this format is to be filled and sent to MPP on a quarterly basis, 10 Business days from end of each calendar quarter.



Compliance Certification:	I hereby certify that all activities performed under the License Agreement have been conducted in accordance with all Applicable Law (as defined in the License Agreement), including, without limitation, with respect to anti-corruption, anti-competition, recalls, safety and reporting requirements, and export controls and sanctions.
	Name: _____ Date: _____ Title: _____

Reporting Template for Compounds

Month	Country	Purchaser	Licensed Product	Quantity (kg)	Total Value (USD)

Compliance Certification:	I hereby certify that all activities performed under the License Agreement have been conducted in accordance with all Applicable Law (as defined in the License Agreement), including, without limitation, with respect to anti-corruption, anti-competition, recalls, safety and reporting requirements, and export controls and sanctions.
	Name: _____ Date: _____ Title: _____